WO2017153640A1 - Dressing in the form of a self-adhesive tape - Google Patents
Dressing in the form of a self-adhesive tape Download PDFInfo
- Publication number
- WO2017153640A1 WO2017153640A1 PCT/FR2016/050529 FR2016050529W WO2017153640A1 WO 2017153640 A1 WO2017153640 A1 WO 2017153640A1 FR 2016050529 W FR2016050529 W FR 2016050529W WO 2017153640 A1 WO2017153640 A1 WO 2017153640A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibers
- polymers
- nonwoven
- dressing according
- fiber
- Prior art date
Links
- 239000002390 adhesive tape Substances 0.000 title abstract 2
- 239000000835 fiber Substances 0.000 claims abstract description 168
- 229920000728 polyester Polymers 0.000 claims abstract description 13
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 12
- 230000023597 hemostasis Effects 0.000 claims abstract description 11
- 230000001737 promoting effect Effects 0.000 claims abstract description 3
- 230000003213 activating effect Effects 0.000 claims abstract 2
- 229920000642 polymer Polymers 0.000 claims description 52
- -1 polyethylene terephthalate Polymers 0.000 claims description 29
- 229920001577 copolymer Polymers 0.000 claims description 15
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 9
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000004952 Polyamide Substances 0.000 claims description 7
- 229920002647 polyamide Polymers 0.000 claims description 7
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 7
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 4
- 238000005192 partition Methods 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 239000004753 textile Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000000853 adhesive Substances 0.000 abstract description 8
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 12
- 230000015271 coagulation Effects 0.000 description 11
- 238000005345 coagulation Methods 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 102000009123 Fibrin Human genes 0.000 description 9
- 108010073385 Fibrin Proteins 0.000 description 9
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 9
- 238000002788 crimping Methods 0.000 description 9
- 229950003499 fibrin Drugs 0.000 description 9
- 229920001281 polyalkylene Polymers 0.000 description 9
- 229920001519 homopolymer Polymers 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000000025 haemostatic effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 229920001651 Cyanoacrylate Polymers 0.000 description 3
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001707 polybutylene terephthalate Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical group C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002201 Oxidized cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- 229920006221 acetate fiber Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940107304 oxidized cellulose Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003445 sucroses Chemical class 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 2
- 229960000401 tranexamic acid Drugs 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- WSQZNZLOZXSBHA-UHFFFAOYSA-N 3,8-dioxabicyclo[8.2.2]tetradeca-1(12),10,13-triene-2,9-dione Chemical compound O=C1OCCCCOC(=O)C2=CC=C1C=C2 WSQZNZLOZXSBHA-UHFFFAOYSA-N 0.000 description 1
- LLLVZDVNHNWSDS-UHFFFAOYSA-N 4-methylidene-3,5-dioxabicyclo[5.2.2]undeca-1(9),7,10-triene-2,6-dione Chemical compound C1(C2=CC=C(C(=O)OC(=C)O1)C=C2)=O LLLVZDVNHNWSDS-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000004953 Aliphatic polyamide Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920000433 Lyocell Polymers 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241000378544 Melaleuca quinquenervia Species 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 229920001283 Polyalkylene terephthalate Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920006292 Polyphenylene isophthalamide Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229920003231 aliphatic polyamide Polymers 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940082620 antifibrinolytics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000011258 core-shell material Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000002350 fibrinopeptide Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920001179 medium density polyethylene Polymers 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- RXOHFPCZGPKIRD-UHFFFAOYSA-N naphthalene-2,6-dicarboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(C(=O)O)=CC=C21 RXOHFPCZGPKIRD-UHFFFAOYSA-N 0.000 description 1
- AKFJWRDCWYYTIG-ZDUSSCGKSA-N naproxcinod Chemical compound C1=C([C@H](C)C(=O)OCCCCO[N+]([O-])=O)C=CC2=CC(OC)=CC=C21 AKFJWRDCWYYTIG-ZDUSSCGKSA-N 0.000 description 1
- 229960003759 naproxcinod Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 229940117969 neopentyl glycol Drugs 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960005113 oxaceprol Drugs 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 1
- 229920006111 poly(hexamethylene terephthalamide) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002215 polytrimethylene terephthalate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 229940019974 pramoxine hydrochloride Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 1
- 229950004154 ravuconazole Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 229920006012 semi-aromatic polyamide Polymers 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 229940009188 silver Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- QOOLLUNRNXQIQF-UHFFFAOYSA-N sodium;5-sulfobenzene-1,3-dicarboxylic acid Chemical compound [Na].OC(=O)C1=CC(C(O)=O)=CC(S(O)(=O)=O)=C1 QOOLLUNRNXQIQF-UHFFFAOYSA-N 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229920006304 triacetate fiber Polymers 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4391—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece characterised by the shape of the fibres
- D04H1/43918—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece characterised by the shape of the fibres nonlinear fibres, e.g. crimped or coiled fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0273—Adhesive bandages for winding around limb, trunk or head, e.g. cohesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01017—Non-adhesive bandages or dressings characterised by the material synthetic, e.g. polymer based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
- A61L15/585—Mixtures of macromolecular compounds
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4326—Condensation or reaction polymers
- D04H1/435—Polyesters
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/44—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling
- D04H1/50—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties the fleeces or layers being consolidated by mechanical means, e.g. by rolling by treatment to produce shrinking, swelling, crimping or curling of fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00463—Plasters use haemostatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- a lesion located on capillaries will involve primary haemostasis that can stop the bleeding by forming a "platelet”.
- Primary haemostasis will be enhanced by plasma coagulation, which will come into play to form an insoluble and solid fibrin clot.
- This clot also serves as a matrix for the migration of cells involved in healing.
- the mechanisms of fibrinolysis will allow clot dissolution, which is an obstacle to free vascular circulation.
- Haemostatic products which promote or activate hemostasis, can intervene at several levels to help stop bleeding. The use of various haemostatic products has long been known to treat hemostasis.
- Haemostatic products act mainly on haemostasis by reproducing the last stage of coagulation. Fibrinogen is transformed into fibrin, under the action of thrombin. Fibrinogen then divides into fibrin and fibrinopeptide monomers. The fibrin monomers aggregate and form a fibrin clot. Physiologically, the activated Factor XIII (FXIIIa) will stabilize the clot by creating internal bonds between the fibrin monomers. During wound healing, the increase in fibrinolytic activity is induced by plasmin, and the degradation of fibrin is initiated. The proteolytic degradation of fibrin can be inhibited by antifibrinolytics (tranexamic acid, aprotinin, etc.).
- Hemostatic products with no specific action on the cascade of events occurring during coagulation will, in turn, contribute to stop bleeding, by acting nonspecifically on the different phases of hemostasis and coagulation.
- collagen examples include collagen, gelatin, the combination of bovine thrombin with gelatin, alginates, oxidized cellulose, polysaccharides, aldehydes, cyanoacrylates or polyethylene glycols.
- Collagen is a tissue protein found in the media of the wall of blood vessels. When vascular breccias appear, circulating platelets are exposed to collagen, adhere to these fibers and initiate their activation process. The contribution of exogenous collagen makes it possible, by increasing the adhesion surface, to promote this step, which results in the formation of the platelet nail and participates in the activation of the coagulation.
- Gelatin is a collagen breakdown product that, in contact with blood, increases in volume and forms a gelatinous plug that fills the wound and mechanically opposes the flow of blood. Under the effect of the expansion of gelatin, the gel becomes saturated with blood, concentrates blood elements and promotes platelet activation. The physical matrix constituted by the gelatin network helps to stabilize the clot.
- bovine thrombin with the gelatin matrix adds a direct action on the coagulation cascade.
- the blood circulates between the gelatin granules and is locally exposed to high concentrations of thrombin, which intervenes to transform the fibrinogen of the patient into fibrin.
- the exchange of Ca 2 + ions of the alginates against the Na + ions of the blood and exudate leads to the gradual transformation of the dry dressing into a gel.
- the release of Ca2 + ions promotes platelet activation and fibrinogenesis.
- the alginate fibers by their physical absorption capacity and their role of matrix participate in the formation of the clot.
- hydrophilic microporous spherical particles of polysaccharides absorb the plasma by osmotic effect, form a gel which fills the wound and act by mechanical blocking of the blood flow.
- the aldehydes act by forming an amide bond between two amino functions present on the amino acids of the tissue proteins and the aldehydes. These covalent bonds make it possible to create a stable bridging between the tissue proteins.
- Cyanoacrylates are composed of various monomers which, under the action of a freshly mixed catalyst, polymerize and harden to form a tissue-adhering film and prevent bleeding by mechanical occlusion of blood flow.
- Polyethylene glycols consist of precursors that, when mixed, polymerize to form a hydrogel. Anchorage of PEG particles to tissue proteins is provided by the formation of covalent bonds and creates a mechanical barrier.
- a product according to the present invention In order to promote or activate hemostasis and particularly to promote or activate wound-related hemostasis, the use of a product according to the present invention has proved its effectiveness in treating and preventing prolonged bleeding. Indeed, it has been demonstrated that the product according to the present invention facilitates the coagulation of blood.
- the dressing When used to stop bleeding, on a finger, for example, the dressing is in the form of a band is laid and wound with one or more turns depending on the strength of the desired band.
- This dressing consists of a self-adhesive elastic band consists of a specific nonwoven which was obtained from short conjugated fibers which were crimped.
- Nonwovens are generally textile materials that can not be used to make medical bandages or bandages because they are not elastic enough or stretchy. Also, have recently been developed nonwovens of curled fibers which have better properties of extensibility. Such products are described in the patent application WO 2008/015972, for their use as a retaining band or bandage, easily tearable.
- this dressing has remarkable haemostatic properties which make it particularly suitable for use in the activation or the promotion of haemostasis.
- the band included in the dressing according to the invention is advantageously self-adhesive.
- the fibers constituting the band are advantageously crimped uniformly in the direction of the thickness of the nonwoven, and have a mean radius of curvature preferably between 10 and 200 microns.
- the number of crimped fibers on the surface of the nonwoven is advantageously greater than 10 crimped fibers / cm.
- the nonwoven preferably has a basis weight of between 10 g / m 2 and 300 g / m 2 .
- the subject of the invention is a dressing comprising a strip consisting of a nonwoven of crimped fibers obtained from conjugated short fibers, in which
- the nonwoven has a basis weight of between 10 g / m 2 and 300 g / m 2 , said fibers are uniformly crimped in the direction of the thickness of the nonwovens, and have an average radius of curvature of between 10 and 200 microns, and
- the number of crimped fibers on the surface of the nonwoven is greater than 10 crimped fibers / cm 2 .
- a variant of the present invention relates to a dressing which, in addition to the band, comprises at least one additional layer on one side of the nonwoven.
- the fibers that have been used to make the nonwoven are preferably conjugated, polymeric in nature, and non-continuous (short).
- the conjugate fibers in the sense of the invention are "latching friable" fibers having an asymmetric or laminated structure, which have the property of curling under the effect of heating. They owe this property to the difference of thermal contraction coefficient of the polymers which constitute them.
- These fibers advantageously consist of at least two polymers which have a different coefficient of thermal contraction.
- These polymers usually have softening points or different melting points. They may be chosen from thermoplastic polymers such as, for example: olefinic polymers (especially polymers of polyolefins C 2 -4 such as low and medium density polyethylenes and polypropylenes), acrylic polymers (especially acrylonitrile polymers with acrylonitrile units) such as acrylonitrile / vinyl chloride copolymers), vinylacetal polymers (especially polyvinyl acetal polymers), chlororovinyl polymers (especially polyvinyl chlorides, vinyl chloride / vinyl acetate copolymers and vinyl chloride / acrylonitrile copolymers) , chlorovinylidene polymers (especially vinylidene chloride / vinyl chloride copolymers and vinylidene chloride / vinyl acetate copolymers), styrenic polymers (especially heat-resistant polysty
- non-adhesive polymers are preferred in wet heat (or water-resistant hydrophobic or non-water-soluble polymers). softening or melting point greater than or equal to 100 ° C, such as, for example, polypropylene polymers, polyester polymers and polyamide polymers. These polymers make it possible to avoid fiber bonding by melting or softening the fibers. Polyester aromatic polymers and polyamide polymers are particularly preferred for their excellent stability, heat resistance and ability to form fibers.
- the fibers used are two-component.
- the two-component fibers may be composed of polymers of the same chemical family or polymers of different chemical families, provided they have different thermal contraction coefficients.
- the conjugated short fibers are bicomponent, the two components constituting them being polymers which have a softening point of greater than or equal to 100 ° C., said polymers being chosen from polypropylene polymers, polyester polymers and polyesters. or the polyamide polymers, and preferably are two different aromatic polyester polymers.
- the two-component fibers consist of two polymers of the same chemical family: for example a homopolymer and a copolymer. It is indeed possible to lower the degree of crystallinity of the homopolymer, or even to make it amorphous, or to lower its melting point or its softening point, by copolymerizing the monomer with another.
- the difference in melting point or softening point of the two polymers may be for example of the order of 5 to 150 ° C, preferably 50 to 130 ° C, and more preferably 70 to 120 ° C.
- the proportion of copolymerizable monomer, relative to the total amount of monomers, is for example of the order of 1 to 50 mol%, preferably 2 to 40 mol%, and more preferably 3 to 30 mol% (particularly from 5 to 20 mol%).
- the weight ratio of the homopolymer and the copolymer can be chosen according to the fiber structure; it is for example, in terms of the homopolymer (A) / copolymer (B) ratio, of the order of 90/10 to 10/90, preferably of 70/30 to 30/70, and more preferably of 60/40 to 40/60.
- the bicomponent fibers consist of two aromatic polyester polymers and in particular the combination of a polyalkylene arylate homopolymer (a) and a polyalkylene arylate copolymer (b).
- the polyalkylene arylate homopolymer (a) may be a homopolymer of an aromatic dicarboxylic acid (especially a symmetrical aromatic dicarboxylic acid such as terephthalic acid or naphthalene-2,6-dicarboxylic acid) and an alkane component diol (especially ethylene glycol or butylene glycol).
- a polymer of the polyalkylene terephthalate series such as polyethylene terephthalate (PET) or polybutylene terephthalate (PBT) is used, and usually a PET with an intrinsic viscosity of the order of 0.6 to 0.7 used for manufacture of ordinary PET fibers.
- PET polyethylene terephthalate
- PBT polybutylene terephthalate
- the polyalkylene arylate copolymer (b) can be obtained from a first monomer for the preparation of the polyalkylene arylate homopolymer (a), and a second monomer selected from a dicarboxylic acid such as a dicarboxylic acid an asymmetric aromatic, an alicyclic dicarboxylic acid, an aliphatic dicarboxylic acid, a longer chain alkane-diol component than the alkane diol of the polyalkylene arylate polymer (a), and / or a diol carrying an ether linkage.
- a dicarboxylic acid such as a dicarboxylic acid an asymmetric aromatic, an alicyclic dicarboxylic acid, an aliphatic dicarboxylic acid, a longer chain alkane-diol component than the alkane diol of the polyalkylene arylate polymer (a), and / or a diol carrying an ether linkage.
- an asymmetric aromatic dicarboxylic acid in particular isophthalic acid, phthalic acid or sodium 5-sulfoisophthalic acid,
- an aliphatic dicarboxylic acid in particular a C 1-12 aliphatic dicarboxylic acid such as adipic acid,
- alkane-diol in particular 1,3-propanediol, 1,4-butanediol, 1,6-hexanediol or neopentylglycol,
- a polyoxyalkylene glycol especially diethylene glycol, triethylene glycol, polyethylene glycol or polytetramethylene glycol.
- an asymmetric aromatic dicarboxylic acid such as isophthalic acid
- a polyoxyalkylene glycol such as diethylene glycol
- the polyalkylene arylate copolymer (b) may optionally be a hard segment elastomer of alkylene arylate (ethylene terephthalate, butylene terephthalate) and flexible segments for example of (poly) oxyalkylene glycol.
- the proportion of dicarboxylic acid component intended to lower the melting point or the softening point relative to the total amount of dicarboxylic acid component is for example of the order of 1 to 50 mol%, preferably 5 to 50% by moles, and more preferably from 15 to 40% by moles.
- the proportion of diol component intended to lower the melting point or the softening point, relative to the total amount of diol component is, for example, at most 30 mol%, and preferably at most 10 mol%, by example of the order of 0.1 to 10 mol%.
- the cross section (perpendicular to the fiber length direction) of two-component fibers is not limited to the round shape (the ordinary form of solid fibers) and the modified shapes (flattened, elliptical, polygonal, 3- to 14-folate , T, H, V, dog bone (i), etc.), but may also be a hollow section.
- the round section is usually chosen.
- phased structures formed by a plurality of polymers for example the heart-shell, island and sea type structures, mixed, parallel (side-by-side or multilayer laminate), radial (radial laminate), hollow radial, block or random.
- these structures it is preferred, for a more spontaneous development of thermal crimping, an eccentric heart-bark type structure or parallel type.
- the core may consist of a polymer of the vinyl alcohol family such as an ethylene / vinyl alcohol copolymer or a polyvinyl alcohol, or a thermoplastic polymer having a melting point or a low softening point, for example a polystyrene or a low density polyethylene, provided that it allows crimping by having a thermal contraction coefficient deviation with the polymer constituting the bark.
- a polymer of the vinyl alcohol family such as an ethylene / vinyl alcohol copolymer or a polyvinyl alcohol
- a thermoplastic polymer having a melting point or a low softening point for example a polystyrene or a low density polyethylene
- the two-component fibers have a side-by-side structure and consist of a first polymer which is a polyethylene terephthalate, and a second polymer which is a copolymer of an alkylene arylate with the isophthalic acid and / or diethylene glycol.
- the average titer of the conjugated short fibers may for example be between 0.1 to 50 dtex, preferably between 0.5 and 10 dtex, and more preferably between 1 and 5 dtex (particularly between 1.5 and 3 dtex). ). If the title is too thin, not only are the fibers difficult to manufacture but they may lack strength. In addition, at the crimping stage, it is difficult to obtain beautiful serpentine crimps. If the title is too big, the fibers become stiff and make it difficult to develop sufficient crimping.
- the average length of the conjugated short fibers before crimping may for example be between 10 and 100 mm, preferably between 20 and 80 mm, and more preferably between 25 and 75 mm (particularly between 40 and 60 mm). If the fibers are too short, in addition to the difficulty of forming the fiber web, entanglement of the fibers is insufficient in the crimping step and it is difficult to guarantee good strength and extensibility properties. If the fibers are too long, not only does it become difficult to form a web of uniformly weighted fibers, but the fibers become entangled excessively during the formation of the web, to the point of interfering with each other at the time of crimping and to prevent the development of extensibility.
- the choice of the length of fiber in the aforesaid range allows some of the crimped fibers on the surface of the nonwoven to emerge moderately from said surface of the nonwoven and thus improve the non-woven self-adhesive which will be discussed later.
- the average titer of the conjugated short fibers is between 1 and 5 dtex, preferably between 1.5 and 3 dtex, and the average length of the conjugated short fibers is between 10 and 100 mm, and preferably between 40 and 60 mm.
- the application of a heat treatment to these conjugate fibers has the effect of developing the crimp and printing them embossed crimps in the form of coils (spiral or "coil spring").
- the average radius of curvature of the crimped fibers in the sense of the invention corresponds to the average radius of curvature of the circles formed by the loops of the coils of the crimped fibers; it may be between 10 and 200 microns, for example between 10 and 250 microns, preferably between 20 and 200 microns, preferably between 50 and 160 microns, and more preferably between 70 and 130 microns.
- the average radius of curvature of the crimped fibers can be determined by electron microscopy according to the following method.
- a photograph (magnification ⁇ 100) of a nonwoven section is taken with a scanning electron microscope (SEM).
- SEM scanning electron microscope
- the fibers appearing on the plate one selects the fibers forming at least 1 spiral turn (serpentine) and one determines their radius of curvature like the radius of the circle traced along the spiral (radius of the circle when one observes the curly fiber in the direction of the axis of the coil).
- the radius of curvature is determined as the half-sum of the large and small diameters of the ellipse.
- the nonwoven according to the invention has the characteristic that the crimping of the conjugate fibers oriented approximately parallel to the planar direction is developed in a substantially uniform manner in the direction of thickness.
- the number of fibers forming at least 1 spiral crimped turn is for example, in the central part (inner layer), from 5 to 50 by 5 mm (planar length) and 0.2 mm (thickness), preferably from 10 to 50 by 5 mm (planar) and 0.2 mm (thickness) and more preferably 20 to 50 per 5 mm (planar) and 0.2 mm (thickness).
- the nonwoven Since most of the curled fibers have their axis oriented in the planar direction and the number of crimps is uniform in the direction of thickness, the nonwoven exhibits a high extensibility (without containing rubber or elastomer), and good operational resistance (without any adhesives).
- areas delimited by a division into three equal parts in the direction of the thickness is meant the different areas obtained when cutting the nonwoven into three equal slices oriented perpendicular to the thickness.
- the uniformity of the crimp in the direction of the thickness can be defined by the ratio of curvature of fiber.
- fiber curl ratio is meant the ratio L2 / L1 of the length of the bilaterally stretched fiber L2 at the distance L1 of both ends of the fiber in the curled state.
- This fiber curvature ratio (in particular in the central region in the direction of the thickness) is for example of the order of at least 1.3 (for example from 1.35 to 5), preferably from 1 to , 4 to 4 (for example from 1.5 to 3.5), and more preferably from 1.6 to 3 (particularly from 1.8 to 2.5).
- the length of fiber L2 does not correspond to the length of the fiber that would be obtained if the three-dimensional curled fiber was stretched and rectilinearized. She corresponds to the length of fiber on the plate that is obtained when stretching and rectilinearizes the fiber appearing curly bidimensionally on the plate. In other words, the fiber length on the plate that is measured according to the invention is less than the actual fiber length.
- the fiber curvature ratio is also uniform in the direction of the thickness.
- the uniformity of the fiber curvature ratio can be evaluated by comparing, in a section taken in the direction of thickness, the fiber curl ratios obtained in the different layers delimited by a partition in three equal parts in the sense of thickness.
- the nonwoven has in a section taken in the direction of the thickness, a fiber curvature ratio of greater than or equal to 1.3 in each of the areas delimited by a division into three equal parts in the sense of thickness, and the ratio of the minimum value to the maximum value of the fiber curl ratio in the different fields is greater than 75%.
- the method of taking a photograph of the nonwoven section under the electron microscope and measuring the fiber curl ratio on selected areas within the different areas of sharing in three equal parts in the direction of thickness is carried out in each of the upper layers (recto domain), internal (central domain) and lower (backside domain), on domains which, in the direction of the length, are at least 2 mm, and in the direction of thickness, are positioned near the center of each layer and have the same thickness from one area to another.
- these measurement domains are parallel in the direction of the thickness, and are defined such that each contains at least 100 fiber fragments allowing the measurement of their curvature ratio (of the order of preferably from minus 300, and more preferably from 500 to 1000).
- the fiber curvature ratio of all the fibers in the domain is measured and the average value is calculated on each measurement domain, then the uniformity of the fiber curl ratio is calculated by comparing the domain showing the largest mean value and the domain showing the smallest mean value.
- the measurement of the fiber curl ratio and its uniformity can be performed according to the following methodology. Take a photo (magnification ⁇ 100) of a section of non-woven fabric under an electron microscope and, in a part where the fibers appeared on the plate, the thickness is divided into three equal areas (front, inner and back layers), and near the center of each domain, measuring domains of at least 2 mm in the length direction and containing at least 500 measurable fiber fragments are defined. On these domains, we measure on the one hand the inter-end distance (the shortest distance) between the two ends of the fiber and on the other hand the fiber length (length of the fiber on the plate).
- the fiber curvature ratio is calculated as the L2 / L1 ratio of the fiber length L2 to the inter-end distance L1 of the fibers. Then we calculate the average on each of the front, inner and back layers of the partition in three equal parts in the direction of the thickness. Finally, the uniformity of the fiber curvature ratio in the direction of the thickness is calculated from the ratio of its maximum and minimum values in the different layers.
- FIGS. 4-a and 4-b of the patent application WO 2008/015972 The principle of the method of measurement of the fiber length is illustrated in FIGS. 4-a and 4-b of the patent application WO 2008/015972.
- Fig.4- (a) illustrates the case of a fiber having one end emerging at the surface and the other end dipping into the nonwoven.
- the inter-end distance L1 is here the distance from one end of the fiber to the dive boundary portion in the nonwoven.
- the length of fiber L2 is the length obtained when the dimension of the observable fiber (part extending from the end of the fiber to the dive portion in the non-dimensional portion) is stretched bilaterally on the plate. woven).
- Fig.4- (b) illustrates the case of a fiber whose two ends plunge into the nonwoven.
- the inter-end distance L1 is here the distance of the two ends of the emerging portion to the surface of the nonwoven (ends on the plate).
- the length of fiber L2 is the length obtained when two-dimensionally stretched, on the plate, the fiber in the part emerging on the surface of the nonwoven.
- the average pitch of the coil is for example of the order of 0.03 to 0.5 mm, preferably of 0.03 to 0.3 mm, and more preferably of 0.05 to 0.2 mm.
- the nonwoven may also contain fibers that are not bi-component fibers.
- additional single-component fibers mention may be made, for example, of the polymer fibers already mentioned above, but also the cellulosic fibers such as, for example, natural fibers (wood wool, sheep's wool, silk, hemp), semi-synthetic fibers. synthetic (especially acetate fibers such as triacetate fibers) or regenerated fibers (rayon, lyocell).
- the average titre and the average length of the single-component fibers are preferably identical to those of the two-component fibers. A single species can be used or several species of these single-component fibers can be combined.
- regenerated fibers such as rayon fibers, semi-synthetic fibers such as acetate fibers, polyolefin fibers such as polypropylene or polyethylene fibers, and polyester fibers. and polyamide fibers.
- the weight ratio between the two-component fibers and the single-component fibers is, for example, of the order of 80/20 to 100/0 (for example from 80/20 to 99/1), preferably from 90/10 to 100/0. and more preferably 95/5 to 100/0.
- the nonwoven may also contain actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retarders.
- actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retarders.
- actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retarders.
- actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retard
- the assets are chosen from: anti-bacterials such as polymyxin B, penicillins (amoxycillin), clavulanic acid, tetracyclines, minocycline, chlorotetracycline, aminoglycosides, amikacin, gentamicin, neomycin, silver and its salts (Sulfadiazine argentic), probiotics;
- anti-bacterials such as polymyxin B, penicillins (amoxycillin), clavulanic acid, tetracyclines, minocycline, chlorotetracycline, aminoglycosides, amikacin, gentamicin, neomycin, silver and its salts (Sulfadiazine argentic), probiotics;
- antiseptics such as sodium mercurothiolate, eosin, chlorhexidine, phenylmercury borate, hydrogen peroxide, Dakin liquor, triclosan, biguanide, hexamidine, thymol, Lugol, Povidone iodine, Merbromine, Benzalkonium and Benzethonium Chloride, ethanol, isopropanol;
- anti-virals such as Acyclovir, Famciclovir, Ritonavir;
- anti fungal agents such as polyenes, Nystatin, Amphotericin B,
- anti-pain agents such as paracetamol, codeine, dextropropoxyphene, tramadol, morphine and its derivatives, corticosteroids and derivatives;
- anti-inflammatories such as glucocorticoids, nonsteroidal anti-inflammatory drugs, aspirin, ibuprofen, ketoprofen, flurbiprofen, diclofenac, aceclofenac, ketorolac, meloxicam, piroxicam, tenoxicam, Naproxen, Indomethacin, Naproxcinod, Nimesulide, Celecoxib, Etoricoxib, Parecoxib, Rofecoxib, Valdecoxib, Phenylbutazone, Niflumic acid, Mefenamic acid, Beta-18-glycyrrhetinic acid;
- - restructuring assets for example rescutants of dander
- rescutants of dander such as silica derivatives, vitamin E, chamomile, calcium, horsetail extract, silk Lipester
- anesthetics such as benzocaine, lidocaine, dibucaine, pramoxine hydrochloride, bupivacaine, mepivacaine, prilocaine and etidocaine.
- haemostatics such as fibrinogen, factor XIII, fibronectin, thrombin, bovine aprotinin, tranexamic acid, collagen, aldehydes, cyanoacrylates, polyethylene glycol, alginates, cellulose, polysaccharides.
- the other mechanical properties of the nonwoven will preferably be as follows.
- the thickness of the nonwoven fabric is advantageously between 0.25 and 5 mm, preferably between 0.4 and 2.5 mm and very particularly between 0.5 and 1.5 mm.
- the thickness can be measured according to EN 9073-2.
- the self-adhesion of the web according to the invention is achieved by the presence of many fibers in the partially free state on the surface of the nonwovens, the surface fibers becoming entangled with each other at the time of the superimposition of the web on it. -even.
- the number of crimped fibers, in particular in the form of a coil or a loop, on the surface of the nonwoven is advantageously greater than 10 crimped fibers / cm 2. and preferably between 10 and 50 crimped fibers / cm 2 .
- a number of crimped fibers on the nonwoven surface of between 10 and 35 crimped fibers / cm 2 will be preferred.
- the number of crimped fibers on the surface of the nonwoven can be determined as follows.
- the self-adhesion characterization of the band is evaluated visually.
- a strip of nonwoven having a width of 15 mm is wound by stretching it slightly on the fingertip so as to form three turns and then torn manually.
- the self-gripping power is then estimated. It follows from this test that the bands remain on the finger for at least 30 minutes.
- This additional layer makes it possible to improve, if necessary, the properties of the self-adhesive elastic band, for example by adapting its absorption, damping, conformability, rigidity or occlusivity capacities.
- materials based on synthetic or natural fibers we can mention woven fabrics, nonwovens, knits, 3D knits, films, foams and their combinations.
- the additional layer may optionally contain active agents that contribute to improving the healing of the wound or that can reduce the pain, or antibacterial agents.
- active agents that contribute to improving the healing of the wound or that can reduce the pain, or antibacterial agents.
- antibacterial fibers for example silver fibers
- an antibacterial agent for example triclosan.
- the example uses a nonwoven, based on two-component asymmetric crimped fibers, manufactured according to the teaching of the patent application WO 2008/015972.
- This nonwoven can be reference SR 0046 from Kuraray.
- This nonwoven is made from the side-by-side fiber, based on polyester copolymers of the company Kuraray whose reference is PN-780.
- the performance of dressings consisting of a web of nonwoven according to the invention on the coagulation of blood was evaluated.
- Whole sheep blood was contacted with a nonwoven web according to the invention at a ratio of 1 cm 2 / mL in test tubes incubated at 37 ⁇ 1 ° C.
- a control tube without tape is tested under the same conditions as a negative control.
- the test tubes are gently inverted every minute until a blood clot is observed.
- the coagulation time is recorded for the article tested (4 trials).
- the average coagulation time of the sheep blood in the presence of the nonwoven according to the invention was 13 minutes thirty seconds.
- the mean clotting time of the sheep blood in the control test tube was about 26 minutes thirty seconds.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Textile Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Mechanical Engineering (AREA)
- Medicinal Chemistry (AREA)
- Nonwoven Fabrics (AREA)
Abstract
The invention relates to a new dressing in the form of a self-adhesive tape to be used for promoting or activating hemostasis. Said tape consists of a self-adhesive nonwoven fabric obtained from agglomerated short fibers that have been crimped. The fibres are preferably made of polyester. The dressing can also include an additional layer.
Description
Pansement se présentant sous la forme d'une bande autoadhérente Dressing in the form of a self-adhesive band
La survenue d'une plaie vasculaire entraîne la mise en place d'un mécanisme de défense pour empêcher la fuite de sang. Une lésion située sur des vaisseaux capillaires va mettre en jeu l'hémostase primaire qui pourra arrêter l'hémorragie par formation d'un « clou plaquettaire ». L'hémostase primaire sera renforcée par la coagulation plasmatique, qui entrera en jeu pour former un caillot de fibrine insoluble et solide. Ce caillot sert également de matrice pour la migration de cellules participant à la cicatrisation. Lorsque la cicatrisation du vaisseau sera terminée, les mécanismes de fïbrinolyse permettront une dissolution du caillot qui constitue un obstacle à la libre circulation vasculaire. Les produits hémostatiques, qui favorisent ou activent l'hémostase, peuvent intervenir à plusieurs niveaux, afin de participer à l'arrêt des saignements. L'utilisation de divers produits hémostatiques est connue depuis longtemps pour traiter l'hémostase. The occurrence of a vascular wound leads to the establishment of a defense mechanism to prevent blood leakage. A lesion located on capillaries will involve primary haemostasis that can stop the bleeding by forming a "platelet". Primary haemostasis will be enhanced by plasma coagulation, which will come into play to form an insoluble and solid fibrin clot. This clot also serves as a matrix for the migration of cells involved in healing. When the healing of the vessel is complete, the mechanisms of fibrinolysis will allow clot dissolution, which is an obstacle to free vascular circulation. Haemostatic products, which promote or activate hemostasis, can intervene at several levels to help stop bleeding. The use of various haemostatic products has long been known to treat hemostasis.
Les produits hémostatiques agissent essentiellement sur l'hémostase en reproduisant la dernière étape de la coagulation. Le fibrinogène se transforme en fibrine, sous l'action de la thrombine. Le fibrinogène se divise alors en monomères de fibrine et fîbrinopeptides. Les monomères de fibrine s'agrègent et forment un caillot de fibrine. Physiologiquement, le Facteur XIII activé (FXIIIa) va stabiliser le caillot en créant des liaisons internes entre les monomères de fibrine. Au cours de la cicatrisation de la plaie, l'augmentation de l'activité fibrinolytique est induite par la plasmine, et la dégradation de la fibrine est initiée. La dégradation protéolytique de la fibrine peut être inhibée par des antifibrinolytiques (acide tranexamique, aprotinine, etc.). Haemostatic products act mainly on haemostasis by reproducing the last stage of coagulation. Fibrinogen is transformed into fibrin, under the action of thrombin. Fibrinogen then divides into fibrin and fibrinopeptide monomers. The fibrin monomers aggregate and form a fibrin clot. Physiologically, the activated Factor XIII (FXIIIa) will stabilize the clot by creating internal bonds between the fibrin monomers. During wound healing, the increase in fibrinolytic activity is induced by plasmin, and the degradation of fibrin is initiated. The proteolytic degradation of fibrin can be inhibited by antifibrinolytics (tranexamic acid, aprotinin, etc.).
Les produits hémostatiques sans action spécifique sur la cascade d'événements survenant au cours de la coagulation vont, quant à eux, contribuer à l'arrêt du saignement, en agissant de manière non spécifique sur les différentes phases d'hémostase et de coagulation. Hemostatic products with no specific action on the cascade of events occurring during coagulation will, in turn, contribute to stop bleeding, by acting nonspecifically on the different phases of hemostasis and coagulation.
Parmi ces produits, on peut citer à titre d'exemple, le collagène, la gélatine, l'association de thrombine bovine à la gélatine, les alginates, la cellulose oxydée, les polysaccharides, les aldéhydes, les cyanoacrylates ou les polyéthylènes glycols. Among these products, there may be mentioned, by way of example, collagen, gelatin, the combination of bovine thrombin with gelatin, alginates, oxidized cellulose, polysaccharides, aldehydes, cyanoacrylates or polyethylene glycols.
Le collagène est une protéine tissulaire présente dans la média de la paroi des vaisseaux sanguins. Lors de l'apparition de brèches vasculaires, les plaquettes circulantes sont exposées au collagène, adhèrent à ces fibres et initient leur processus d'activation. L'apport de collagène exogène permet, en augmentant la surface d'adhésion, de promouvoir cette étape, qui aboutit à la formation du clou plaquettaire et participe à l'activation de la coagulation.
La gélatine est un produit de dégradation du collagène qui, au contact du sang, augmente de volume et forme un bouchon gélatineux qui comble la plaie et s'oppose mécaniquement à l'écoulement du sang. Sous l'effet de l'expansion de la gélatine, le gel se sature de sang, concentre des éléments sanguins et favorise l'activation plaquettaire. La matrice physique constituée par le réseau de gélatine aide à stabiliser le caillot. Collagen is a tissue protein found in the media of the wall of blood vessels. When vascular breccias appear, circulating platelets are exposed to collagen, adhere to these fibers and initiate their activation process. The contribution of exogenous collagen makes it possible, by increasing the adhesion surface, to promote this step, which results in the formation of the platelet nail and participates in the activation of the coagulation. Gelatin is a collagen breakdown product that, in contact with blood, increases in volume and forms a gelatinous plug that fills the wound and mechanically opposes the flow of blood. Under the effect of the expansion of gelatin, the gel becomes saturated with blood, concentrates blood elements and promotes platelet activation. The physical matrix constituted by the gelatin network helps to stabilize the clot.
L'association de thrombine bovine à la matrice de gélatine ajoute une action directe sur la cascade de la coagulation. Le sang circule entre les granules de gélatine et se trouve localement exposé à des concentrations élevées de thrombine, qui intervient pour transformer le fïbrinogène du patient en fibrine. The combination of bovine thrombin with the gelatin matrix adds a direct action on the coagulation cascade. The blood circulates between the gelatin granules and is locally exposed to high concentrations of thrombin, which intervenes to transform the fibrinogen of the patient into fibrin.
Au contact des liquides biologiques, l'échange des ions Ca2+ des alginates contre les ions Na+ du sang et de Γ exsudât entraîne la transformation progressive du pansement sec en un gel. La libération des ions Ca2+ favorise l'activation plaquettaire et la fïbrino-formation. Les fibres d'alginates par leur capacité physique d'absorption et leur rôle de matrice participent à la formation du caillot. In contact with biological fluids, the exchange of Ca 2 + ions of the alginates against the Na + ions of the blood and exudate leads to the gradual transformation of the dry dressing into a gel. The release of Ca2 + ions promotes platelet activation and fibrinogenesis. The alginate fibers by their physical absorption capacity and their role of matrix participate in the formation of the clot.
Une fois saturée de sang, la cellulose oxydée gonfle et se transforme en une masse gélatineuse noire ou brune qui contribue à la formation du caillot. Cette action semble être due à un effet physique par compression et absorption du sang, plutôt qu'à une modification du mécanisme physiologique normal de la coagulation. Once saturated with blood, the oxidized cellulose swells and turns into a black or brown gelatinous mass that contributes to clot formation. This action seems to be due to a physical effect by compression and absorption of the blood, rather than a modification of the normal physiological mechanism of coagulation.
Les particules sphériques microporeuses hydrophiles de polysaccharides absorbent par effet osmotique le plasma, forment un gel qui comble la plaie et agissent par blocage mécanique du flux sanguin. The hydrophilic microporous spherical particles of polysaccharides absorb the plasma by osmotic effect, form a gel which fills the wound and act by mechanical blocking of the blood flow.
Les aldéhydes agissent par formation d'une liaison amide entre deux fonctions aminés présentes sur les acides aminés des protéines tissulaires et les aldéhydes. Ces liaisons covalentes permettent de créer un pontage stable entre les protéines tissulaires. The aldehydes act by forming an amide bond between two amino functions present on the amino acids of the tissue proteins and the aldehydes. These covalent bonds make it possible to create a stable bridging between the tissue proteins.
Les cyanoacrylates sont composés de différents monomères qui, sous l'action d'un catalyseur mélangé extemporanément, polymérisent et durcissent pour former un film adhérant aux tissus et prévenir les saignements par occlusion mécanique du flux sanguin. Cyanoacrylates are composed of various monomers which, under the action of a freshly mixed catalyst, polymerize and harden to form a tissue-adhering film and prevent bleeding by mechanical occlusion of blood flow.
Les Polyéthylène glycols (PEG) sont constituées de précurseurs qui, une fois mélangés, polymérisent pour former un hydrogel. L'ancrage des particules de PEG aux protéines tissulaires est assuré par la formation de liaisons covalentes et créé une barrière mécanique. Polyethylene glycols (PEGs) consist of precursors that, when mixed, polymerize to form a hydrogel. Anchorage of PEG particles to tissue proteins is provided by the formation of covalent bonds and creates a mechanical barrier.
Afin de favoriser ou d'activer l'hémostase et tout particulièrement favoriser ou activer l'hémostase liée aux plaies, l'utilisation d'un produit selon la présente invention a prouvé
son efficacité pour soigner et éviter les saignements prolongés. En effet, il a été démontré que le produit selon la présente invention facilitait la coagulation du sang. In order to promote or activate hemostasis and particularly to promote or activate wound-related hemostasis, the use of a product according to the present invention has proved its effectiveness in treating and preventing prolonged bleeding. Indeed, it has been demonstrated that the product according to the present invention facilitates the coagulation of blood.
Lors de son utilisation pour stopper un saignement, sur un doigt par exemple, le pansement se présentant sous la forme d'une bande est posé et enroulé avec une ou plusieurs spires en fonction de la tenue de la bande désirée. When used to stop bleeding, on a finger, for example, the dressing is in the form of a band is laid and wound with one or more turns depending on the strength of the desired band.
Le pansement selon la présente invention présente l'avantage : The dressing according to the present invention has the advantage:
- d'être facile et rapide à poser, - to be easy and quick to ask,
- d'être peu épais, ce qui permet d'améliorer son confort et sa conformabilité, - To be thin, which improves its comfort and conformability,
- de ne pas utiliser de latex ou d'adhésif susceptible de venir au contact de la peau,- do not use latex or adhesive that may come into contact with the skin,
- d'être déchirable. - to be tearable.
Ce pansement est composé d'une bande élastique autoadhérente est constitué d'un non tissé spécifique qui a été obtenu à partir de fibres conjuguées courtes qui ont été frisées. This dressing consists of a self-adhesive elastic band consists of a specific nonwoven which was obtained from short conjugated fibers which were crimped.
Les non tissés sont généralement des matériaux textiles qui ne peuvent servir à fabriquer des bandes ou des bandages médicaux parce qu'ils ne sont pas assez élastiques ou extensibles. Aussi, ont été récemment mis au point des non tissés de fibres frisées qui présentent de meilleures propriétés d'extensibilité. De tels produits sont décrits dans la demande de brevet WO 2008/015972, pour leur utilisation comme bande de maintien ou de bandage, aisément déchirables. Nonwovens are generally textile materials that can not be used to make medical bandages or bandages because they are not elastic enough or stretchy. Also, have recently been developed nonwovens of curled fibers which have better properties of extensibility. Such products are described in the patent application WO 2008/015972, for their use as a retaining band or bandage, easily tearable.
De façon tout à fait surprenante, ce pansement présente des propriétés hémostatiques remarquables qui la rendent particulièrement adaptée à une utilisation dans l'activation ou la favorisation de l'hémostase. Surprisingly, this dressing has remarkable haemostatic properties which make it particularly suitable for use in the activation or the promotion of haemostasis.
La bande comprise dans le pansement selon l'invention est avantageusement autoadhérente. The band included in the dressing according to the invention is advantageously self-adhesive.
Les fibres constituant la bande sont avantageusement frisées de façon uniforme dans le sens de l'épaisseur du non tissé, et présentent un rayon de courbure moyen de préférence compris entre 10 et 200 micromètres. Le nombre de fibres frisées à la surface du non-tissé est avantageusement supérieur à 10 fibres frisées/cm . The fibers constituting the band are advantageously crimped uniformly in the direction of the thickness of the nonwoven, and have a mean radius of curvature preferably between 10 and 200 microns. The number of crimped fibers on the surface of the nonwoven is advantageously greater than 10 crimped fibers / cm.
Le non tissé a de préférence un grammage compris entre 10 g/m2 et 300 g/m2. The nonwoven preferably has a basis weight of between 10 g / m 2 and 300 g / m 2 .
Dans un mode de réalisation particulier, l'invention a pour objet un pansement comprenant une bande constitué d'un non tissé de fibres frisées obtenues à partir de fibres courtes conjuguées, dans laquelle In a particular embodiment, the subject of the invention is a dressing comprising a strip consisting of a nonwoven of crimped fibers obtained from conjugated short fibers, in which
- le non tissé a un grammage compris entre 10 g/m2 et 300 g/m2,
- lesdites fibres sont frisées de façon uniforme dans le sens de l'épaisseur des non tissés, et présentent un rayon de courbure moyen compris entre 10 et 200 micromètres, et the nonwoven has a basis weight of between 10 g / m 2 and 300 g / m 2 , said fibers are uniformly crimped in the direction of the thickness of the nonwovens, and have an average radius of curvature of between 10 and 200 microns, and
- le nombre de fibres frisées à la surface du non-tissé est supérieur à 10 fibres frisées/cm2. the number of crimped fibers on the surface of the nonwoven is greater than 10 crimped fibers / cm 2 .
Une variante de la présente invention est relative à un pansement qui, en plus de la bande, comprend au moins une couche supplémentaire sur une des faces du non tissé. A variant of the present invention relates to a dressing which, in addition to the band, comprises at least one additional layer on one side of the nonwoven.
Le non tissé utilisable dans le cadre de la présente invention est décrit dans la demande de brevet WO 2008/015972. The nonwoven used in the context of the present invention is described in the patent application WO 2008/015972.
De façon générale, les fibres qui ont été utilisées pour fabriquer le non tissé sont de préférence conjuguées, de nature polymérique, et non continues (courtes). In general, the fibers that have been used to make the nonwoven are preferably conjugated, polymeric in nature, and non-continuous (short).
Les fibres conjuguées au sens de l'invention sont des fibres «à frisabilité latente» dotées d'une structure asymétrique ou stratifiée, qui ont la propriété de friser sous l'effet d'un chauffage. Elles doivent cette propriété à la différence de coefficient de contraction thermique des polymères qui les constituent. The conjugate fibers in the sense of the invention are "latching friable" fibers having an asymmetric or laminated structure, which have the property of curling under the effect of heating. They owe this property to the difference of thermal contraction coefficient of the polymers which constitute them.
Ces fibres sont avantageusement constituées d'au moins deux polymères qui présentent un coefficient de contraction thermique différent. Ces polymères ont ordinairement des points de ramollissement ou des points de fusion différents. Ils peuvent être choisis parmi les polymères thermoplastiques comme par exemple : les polymères oléfmiques (notamment les polymères de polyoléfïnes C2-4 tels que les polyéthylènes et polypropylènes basse, moyenne et haute densité), les polymères acryliques (notamment les polymères acrylonitriliques à unités acrylonitrile tels que les copolymères acrylonitrile/chlorure de vinyle), les polymères vinylacétaliques (notamment les polymères de polyvinylacétal), les polymères chlororovinyliques (notamment les polychlorures de vinyle, les copolymères chlorure de vinyle/acétate de vinyle et les copolymères chlorure de vinyle/acrylonitrile), les polymères chlorovinylidéniques (notamment les copolymères chlorure de vinylidène/chlorure de vinyle et les copolymères chlorure de vinylidène/acétate de vinyle), les polymères styréniques (notamment les polystyrènes résistants à la chaleur), les polymères polyesters (notamment les polymères de polyalkylène C2_4 arylates tels que les polymères de polyéthylène téréphtalate, de polytriméthylène téréphtalate, de polybutylène téréphtalate et de polyéthylène naphtalate), les polymères polyamides (notamment les polymères polyamides aliphatiques tels que les polyamides 6, 6-6, 11, 12, 6-10 et 6-12, les polymères polyamides semi-aromatiques, les polymères polyamides aromatiques tels que le polyphénylène isophtalamide, le
polyhexaméthylène téréphtalamide et le polyparaphénylène téréphtalamide), les polymères polycarbonates (notamment les polycarbonates de type bisphénol A), les polymères de polyparaphénylène benzobisoxazole, les polymères de polysulfure de phénylène, les polymères polyuréthanes, les polymères cellulosiques (notamment les esters de cellulose), etc. Ces polymères thermoplastiques peuvent éventuellement contenir d'autres unités copolymérisables. These fibers advantageously consist of at least two polymers which have a different coefficient of thermal contraction. These polymers usually have softening points or different melting points. They may be chosen from thermoplastic polymers such as, for example: olefinic polymers (especially polymers of polyolefins C 2 -4 such as low and medium density polyethylenes and polypropylenes), acrylic polymers (especially acrylonitrile polymers with acrylonitrile units) such as acrylonitrile / vinyl chloride copolymers), vinylacetal polymers (especially polyvinyl acetal polymers), chlororovinyl polymers (especially polyvinyl chlorides, vinyl chloride / vinyl acetate copolymers and vinyl chloride / acrylonitrile copolymers) , chlorovinylidene polymers (especially vinylidene chloride / vinyl chloride copolymers and vinylidene chloride / vinyl acetate copolymers), styrenic polymers (especially heat-resistant polystyrenes), polyester polymers (especially polyalkylene polymers C 2 _ 4 arylates such as polymers of polyethylene terephthalate, polytrimethylene terephthalate, polybutylene terephthalate and polyethylene naphthalate), polyamide polymers (especially aliphatic polyamide polymers such as polyamides 6, 6-6, 11, 12, 6-10 and 6 -12, semi-aromatic polyamide polymers, aromatic polyamide polymers such as polyphenylene isophthalamide, polyhexamethylene terephthalamide and polyparaphenylene terephthalamide), polycarbonate polymers (especially bisphenol A type polycarbonates), polyparaphenylene benzobisoxazole polymers, phenylene polysulfide polymers, polyurethane polymers, cellulosic polymers (especially cellulose esters), and the like. . These thermoplastic polymers may optionally contain other copolymerizable units.
Lorsque le chauffage des fibres est réalisé avec de la vapeur à haute température, selon le mode préféré de réalisation du non tissé, on préfère des polymères non adhésifs sous chaleur humide (ou des polymères hydrophobes ou non hydrosolubles résistants à la chaleur) de point de ramollissement ou de point de fusion supérieur ou égal à 100°C, comme par exemple les polymères polypropyléniques, les polymères polyesters et les polymères polyamides. Ces polymères permettent d'éviter le collage des fibres par fusion ou le ramollissement des fibres. On préfère tout particulièrement les polymères polyesters aromatiques et les polymères polyamides, pour leur excellente stabilité, leur résistance à la chaleur et leur aptitude à former des fibres. When the heating of the fibers is carried out with high temperature steam, according to the preferred embodiment of the nonwoven, non-adhesive polymers are preferred in wet heat (or water-resistant hydrophobic or non-water-soluble polymers). softening or melting point greater than or equal to 100 ° C, such as, for example, polypropylene polymers, polyester polymers and polyamide polymers. These polymers make it possible to avoid fiber bonding by melting or softening the fibers. Polyester aromatic polymers and polyamide polymers are particularly preferred for their excellent stability, heat resistance and ability to form fibers.
Selon un mode préféré de la présente invention les fibres utilisées sont bicomposants. Les fibres bicomposants peuvent être composées de polymères de la même famille chimique ou de polymères de familles chimiques différentes, pourvu qu'ils aient des coefficients de contraction thermiques différents. According to a preferred embodiment of the present invention the fibers used are two-component. The two-component fibers may be composed of polymers of the same chemical family or polymers of different chemical families, provided they have different thermal contraction coefficients.
Dans un mode de mise en œuvre, les fibres courtes conjuguées sont bicomposants, les deux composants les constituant étant des polymères qui présentent un point de ramollissement supérieur ou égal à 100°C, lesdits polymères étant choisis parmi les polymères polypropyléniques, les polymères polyesters et/ou les polymères polyamides, et de préférence sont deux polymères polyesters aromatiques différents. In one embodiment, the conjugated short fibers are bicomponent, the two components constituting them being polymers which have a softening point of greater than or equal to 100 ° C., said polymers being chosen from polypropylene polymers, polyester polymers and polyesters. or the polyamide polymers, and preferably are two different aromatic polyester polymers.
On préfère que les fibres bicomposants soient constituées de deux polymères de la même famille chimique : par exemple d'un homopolymère et d'un copolymère. On peut en effet abaisser le taux de cristallinité de l'homopolymère, voire le rendre amorphe, ou abaisser son point de fusion ou son point de ramollissement, en copolymérisant le monomère avec un autre. L'écart de point de fusion ou de point de ramollissement des deux polymères peut être par exemple de l'ordre de 5 à 150°C, préférentiellement de 50 à 130°C, et plus préférentiellement de 70 à 120°C. La proportion de monomère copolymérisable, rapportée à la quantité totale de monomères, est par exemple de l'ordre de 1 à 50 % en moles, préférentiellement de 2 à 40 % en moles, et plus préférentiellement de 3 à 30 % en moles (particulièrement de 5 à 20 % en moles). Le rapport pondéral de l'homopolymère et du copolymère peut être choisi en fonction de la
structure des fibres; il est par exemple, en termes de rapport homopolymère (A)/copolymère (B), de l'ordre de 90/10 à 10/90, préférentiellement de 70/30 à 30/70, et plus préférentiellement de 60/40 à 40/60. Dans un mode de réalisation préféré, les fibres bicomposants sont constituées de deux polymères polyesters aromatiques et en particulier de l'association d'un homopolymère de polyalkylène arylate (a) et d'un copolymère de polyalkylène arylate (b). L'homopolymère de polyalkylène arylate (a) peut être un homopolymère d'un acide dicarboxylique aromatique (notamment un acide dicarboxylique aromatique symétrique tel que l'acide téréphtalique ou l'acide naphtalène-2,6-dicarboxylique) et d'un composant alcane-diol (notamment l'éthylène- glycol ou le butylène-glycol). On utilise par exemple un polymère de la série des polyalkylène téréphtalates tel que le polyéthylène téréphtalate (PET) ou le polybutylène téréphtalate (PBT), et ordinairement un PET de viscosité intrinsèque de l'ordre de 0,6 à 0,7 servant à la fabrication des fibres de PET ordinaires. Le copolymère de polyalkylène arylate (b) peut être obtenu à partir d'un premier monomère servant à la préparation de l'homopolymère de polyalkylène arylate (a), et d'un deuxième monomère choisi parmi un acide dicarboxylique tel qu'un acide dicarboxylique aromatique asymétrique, un acide dicarboxylique alicyclique, un acide dicarboxylique aliphatique, un composant alcane-diol de chaîne plus longue que l'alcane-diol du polymère de polyalkylène arylate (a), et/ou un diol porteur d'une liaison éther. It is preferred that the two-component fibers consist of two polymers of the same chemical family: for example a homopolymer and a copolymer. It is indeed possible to lower the degree of crystallinity of the homopolymer, or even to make it amorphous, or to lower its melting point or its softening point, by copolymerizing the monomer with another. The difference in melting point or softening point of the two polymers may be for example of the order of 5 to 150 ° C, preferably 50 to 130 ° C, and more preferably 70 to 120 ° C. The proportion of copolymerizable monomer, relative to the total amount of monomers, is for example of the order of 1 to 50 mol%, preferably 2 to 40 mol%, and more preferably 3 to 30 mol% (particularly from 5 to 20 mol%). The weight ratio of the homopolymer and the copolymer can be chosen according to the fiber structure; it is for example, in terms of the homopolymer (A) / copolymer (B) ratio, of the order of 90/10 to 10/90, preferably of 70/30 to 30/70, and more preferably of 60/40 to 40/60. In a preferred embodiment, the bicomponent fibers consist of two aromatic polyester polymers and in particular the combination of a polyalkylene arylate homopolymer (a) and a polyalkylene arylate copolymer (b). The polyalkylene arylate homopolymer (a) may be a homopolymer of an aromatic dicarboxylic acid (especially a symmetrical aromatic dicarboxylic acid such as terephthalic acid or naphthalene-2,6-dicarboxylic acid) and an alkane component diol (especially ethylene glycol or butylene glycol). For example, a polymer of the polyalkylene terephthalate series such as polyethylene terephthalate (PET) or polybutylene terephthalate (PBT) is used, and usually a PET with an intrinsic viscosity of the order of 0.6 to 0.7 used for manufacture of ordinary PET fibers. The polyalkylene arylate copolymer (b) can be obtained from a first monomer for the preparation of the polyalkylene arylate homopolymer (a), and a second monomer selected from a dicarboxylic acid such as a dicarboxylic acid an asymmetric aromatic, an alicyclic dicarboxylic acid, an aliphatic dicarboxylic acid, a longer chain alkane-diol component than the alkane diol of the polyalkylene arylate polymer (a), and / or a diol carrying an ether linkage.
Il est possible d'utiliser un seul ou d'associer plusieurs de ces deuxièmes monomères. Parmi ces composants, on utilise de préférence : It is possible to use one or to associate several of these second monomers. Among these components, use is preferably made of:
- un acide dicarboxylique aromatique asymétrique, notamment l'acide isophtalique, l'acide phtalique ou l'acide 5-sulfoisophtalique de sodium, an asymmetric aromatic dicarboxylic acid, in particular isophthalic acid, phthalic acid or sodium 5-sulfoisophthalic acid,
- ou un acide dicarboxylique aliphatique, notamment un acide dicarboxylique aliphatique C1-12 tel que l'acide adipique, or an aliphatic dicarboxylic acid, in particular a C 1-12 aliphatic dicarboxylic acid such as adipic acid,
- un alcane-diol, notamment le 1,3-propane-diol, le 1 ,4-butane-diol, le 1,6-hexane- diol ou le néopentylglycol, an alkane-diol, in particular 1,3-propanediol, 1,4-butanediol, 1,6-hexanediol or neopentylglycol,
- un polyoxyalkylène-glycol, notamment le diéthylène-glycol, le triéthylène-glycol, le polyéthylène-glycol ou le polytétraméthylène-glycol. a polyoxyalkylene glycol, especially diethylene glycol, triethylene glycol, polyethylene glycol or polytetramethylene glycol.
Parmi eux, on choisit de préférence notamment un acide dicarboxylique aromatique asymétrique tel que l'acide isophtalique, et un polyoxyalkylène-glycol tel que le diéthylène- glycol. Le copolymère de polyalkylène arylate (b) peut éventuellement être un élastomère à segments durs d'alkylène arylate (éthylène téréphtalate, butylène téréphtalate) et à segments souples par exemple de (poly)oxyalkylène-glycol. Dans le copolymère de polyalkylène arylate
(b), la proportion de composant acide dicarboxylique destiné à abaisser le point de fusion ou le point de ramollissement rapportée à la quantité totale de composant acide dicarboxylique est par exemple de l'ordre de 1 à 50 % en moles, préférentiellement de 5 à 50 % en moles, et plus préférentiellement de 15 à 40 % en moles. La proportion de composant diol destiné à abaisser le point de fusion ou le point de ramollissement rapportée à la quantité totale de composant diol, est par exemple d'au plus 30 % en moles, et préférentiellement d'au plus 10 % en moles, par exemple de l'ordre de 0,1 à 10 % en moles. Among them, there is preferably chosen an asymmetric aromatic dicarboxylic acid such as isophthalic acid, and a polyoxyalkylene glycol such as diethylene glycol. The polyalkylene arylate copolymer (b) may optionally be a hard segment elastomer of alkylene arylate (ethylene terephthalate, butylene terephthalate) and flexible segments for example of (poly) oxyalkylene glycol. In the polyalkylene arylate copolymer (b), the proportion of dicarboxylic acid component intended to lower the melting point or the softening point relative to the total amount of dicarboxylic acid component is for example of the order of 1 to 50 mol%, preferably 5 to 50% by moles, and more preferably from 15 to 40% by moles. The proportion of diol component intended to lower the melting point or the softening point, relative to the total amount of diol component, is, for example, at most 30 mol%, and preferably at most 10 mol%, by example of the order of 0.1 to 10 mol%.
La section transversale (perpendiculaire au sens de la longueur des fibres) des fibres bicomposants n'est pas limitée à la forme ronde (la forme ordinaire des fibres pleines) et aux formes modifiées (aplatie, elliptique, polygonale, 3- à 14-foliée, en T, en H, en V, en «os à chien» (en i), etc.), mais peut être aussi une section creuse. Toutefois, on choisit usuellement la section ronde. The cross section (perpendicular to the fiber length direction) of two-component fibers is not limited to the round shape (the ordinary form of solid fibers) and the modified shapes (flattened, elliptical, polygonal, 3- to 14-folate , T, H, V, dog bone (i), etc.), but may also be a hollow section. However, the round section is usually chosen.
Pour la structure transversale des fibres bicomposants, on peut citer les structures phasées formées par une pluralité de polymères, comme par exemple les structures de types cœur-écorce, îles et mer, mélangé, parallèle (côte-à-côte ou laminé multicouche), radial (laminé radial), radial creux, à blocs ou aléatoire. Parmi ces structures, on préfère, pour un développement plus spontané du frisage thermique, une structure de type cœur-écorce excentrique ou de type parallèle. Dans le cas de fibres bicomposants de type cœur-écorce et par exemple de type cœur-écorce excentrique, l'âme peut être constituée d'un polymère de la famille de l'alcool vinylique tel qu'un copolymère éthylène/alcool vinylique ou un alcool polyvinylique, ou d'un polymère thermoplastique de point de fusion ou de point de ramollissement bas, par exemple un polystyrène ou un polyéthylène basse densité, pourvu qu'elle autorise le frisage par le fait d'avoir un écart de coefficient de contraction thermique avec le polymère constituant l'écorce. For the transverse structure of the bicomponent fibers, mention may be made of the phased structures formed by a plurality of polymers, for example the heart-shell, island and sea type structures, mixed, parallel (side-by-side or multilayer laminate), radial (radial laminate), hollow radial, block or random. Among these structures, it is preferred, for a more spontaneous development of thermal crimping, an eccentric heart-bark type structure or parallel type. In the case of two-component fibers of the core-shell type and for example of the eccentric core-bark type, the core may consist of a polymer of the vinyl alcohol family such as an ethylene / vinyl alcohol copolymer or a polyvinyl alcohol, or a thermoplastic polymer having a melting point or a low softening point, for example a polystyrene or a low density polyethylene, provided that it allows crimping by having a thermal contraction coefficient deviation with the polymer constituting the bark.
Dans un mode de réalisation particulier, les fibres bicomposants ont une structure de type côte à côte et sont constituées d'un premier polymère qui est un polyéthylène téréphtalate, et d'un second polymère qui est un copolymère d'un alkylène arylate avec l'acide isophtalique et/ou du diéthylène glycol. In a particular embodiment, the two-component fibers have a side-by-side structure and consist of a first polymer which is a polyethylene terephthalate, and a second polymer which is a copolymer of an alkylene arylate with the isophthalic acid and / or diethylene glycol.
Le titre moyen des fibres courtes conjuguées, notamment bicomposants, peut être par exemple compris entre 0,1 à 50 dtex, préférentiellement entre 0,5 et 10 dtex, et plus préférentiellement entre 1 et 5 dtex (particulièrement entre 1,5 et 3 dtex). Si le titre est trop fin, non seulement les fibres sont difficiles à fabriquer mais elles risquent de manquer de résistance.
De plus, à l'étape de frisage, il est difficile d'obtenir de belles frisures en serpentin. Si le titre est trop gros, les fibres deviennent raides et rendent difficile le développement d'un frisage suffisant. The average titer of the conjugated short fibers, in particular two-component, may for example be between 0.1 to 50 dtex, preferably between 0.5 and 10 dtex, and more preferably between 1 and 5 dtex (particularly between 1.5 and 3 dtex). ). If the title is too thin, not only are the fibers difficult to manufacture but they may lack strength. In addition, at the crimping stage, it is difficult to obtain beautiful serpentine crimps. If the title is too big, the fibers become stiff and make it difficult to develop sufficient crimping.
La longueur moyenne des fibres courtes conjuguées avant le frisage peut être par exemple comprise entre 10 et 100 mm, préférentiellement entre 20 et 80 mm, et plus préférentiellement entre 25 et 75 mm (particulièrement entre 40 et 60 mm). Si les fibres sont trop courtes, outre la difficulté de former le voile de fibres, l'enchevêtrement des fibres est insuffisant à l'étape de frisage et il est difficile de garantir de bonnes propriétés de résistance et d'extensibilité. Si les fibres sont trop longues, non seulement il devient difficile de former un voile de fibres de grammage uniforme, mais les fibres s'enchevêtrent excessivement lors de la formation du voile, au point de se gêner mutuellement au moment du frisage et d'empêcher le développement de l'extensibilité. De plus, dans l'invention, le choix de la longueur de fibre dans la plage précitée permet à une partie des fibres frisées à la surface du non-tissé d'émerger modérément de ladite surface du non-tissé et ainsi d'améliorer l'auto-adhésivité du non-tissé qui sera évoquée plus loin. The average length of the conjugated short fibers before crimping may for example be between 10 and 100 mm, preferably between 20 and 80 mm, and more preferably between 25 and 75 mm (particularly between 40 and 60 mm). If the fibers are too short, in addition to the difficulty of forming the fiber web, entanglement of the fibers is insufficient in the crimping step and it is difficult to guarantee good strength and extensibility properties. If the fibers are too long, not only does it become difficult to form a web of uniformly weighted fibers, but the fibers become entangled excessively during the formation of the web, to the point of interfering with each other at the time of crimping and to prevent the development of extensibility. In addition, in the invention, the choice of the length of fiber in the aforesaid range allows some of the crimped fibers on the surface of the nonwoven to emerge moderately from said surface of the nonwoven and thus improve the non-woven self-adhesive which will be discussed later.
Dans un mode de réalisation, le titre moyen des fibres courtes conjuguées est compris entre 1 et 5 dtex, de préférence entre 1,5 et 3 dtex, et la longueur moyenne des fibres courtes conjuguées est comprise entre 10 à 100 mm, et de préférence entre 40 et 60 mm. In one embodiment, the average titer of the conjugated short fibers is between 1 and 5 dtex, preferably between 1.5 and 3 dtex, and the average length of the conjugated short fibers is between 10 and 100 mm, and preferably between 40 and 60 mm.
L'application d'un traitement thermique à ces fibres conjuguées a pour effet de développer le frisage et de leur imprimer des frisures en relief ayant la forme de serpentins (en spirale ou en «ressort à boudin»). Le rayon de courbure moyen des fibres frisées au sens de l'invention correspond au rayon de courbure moyen des cercles formés par les boucles des serpentins des fibres frisées ; il peut compris entre 10 et 200 microns, par exemple entre 10 et 250 microns, de préférence entre 20 et 200 microns, préférentiellement entre 50 et 160 microns, et plus préférentiellement entre 70 et 130 microns. The application of a heat treatment to these conjugate fibers has the effect of developing the crimp and printing them embossed crimps in the form of coils (spiral or "coil spring"). The average radius of curvature of the crimped fibers in the sense of the invention corresponds to the average radius of curvature of the circles formed by the loops of the coils of the crimped fibers; it may be between 10 and 200 microns, for example between 10 and 250 microns, preferably between 20 and 200 microns, preferably between 50 and 160 microns, and more preferably between 70 and 130 microns.
Le rayon de courbure moyen des fibres frisées peut être déterminé par microscopie électronique selon la méthode suivante. On prend une photo (grossissement xlOO) d'une section de non-tissé au microscope électronique à balayage (MEB). Parmi les fibres apparaissant sur le cliché, on sélectionne les fibres formant au moins 1 tour de spirale (serpentin) et on détermine leur rayon de courbure comme le rayon du cercle tracé le long de la spirale (rayon du cercle quand on observe la fibre frisée dans le sens de l'axe du serpentin). Quand la fibre dessine une spirale elliptique, le rayon de courbure est déterminé comme la demi-somme des grand et petit diamètres de l'ellipse. Afin d'exclure les fibres ayant développé un frisage en serpentin
insuffisant et les fibres apparaissant elliptiques à cause d'une observation oblique de la spirale, on s'est limité aux fibres elliptiques de rapport entre grand et petit diamètres compris entre 0,8 et 1,2. On réalise la mesure sur l'image MEB d'une section arbitraire de non tissé et on détermine la moyenne sur une population de fibres n=100. The average radius of curvature of the crimped fibers can be determined by electron microscopy according to the following method. A photograph (magnification × 100) of a nonwoven section is taken with a scanning electron microscope (SEM). Among the fibers appearing on the plate, one selects the fibers forming at least 1 spiral turn (serpentine) and one determines their radius of curvature like the radius of the circle traced along the spiral (radius of the circle when one observes the curly fiber in the direction of the axis of the coil). When the fiber draws an elliptical spiral, the radius of curvature is determined as the half-sum of the large and small diameters of the ellipse. To exclude fibers that have developed serpentine crimp insufficient and fibers appearing elliptical because of an oblique observation of the spiral, it was limited to elliptical fibers of ratio between large and small diameters between 0.8 and 1.2. The measurement on the SEM image of an arbitrary nonwoven section is made and the average is determined on a population of fibers n = 100.
Lorsque le frisage est réalisé par de la vapeur à haute température, le non-tissé selon l'invention a pour caractéristique que le frisage des fibres conjuguées orientées à peu près parallèlement au sens planaire est développé de façon à peu près uniforme dans le sens de l'épaisseur. Dans une section de non tissé prise dans le sens de l'épaisseur, parmi les domaines délimités par un partage en trois parts égales dans le sens de l'épaisseur, le nombre de fibres formant au moins 1 tour de frisure spiralée est par exemple, dans la partie centrale (couche interne), de 5 à 50 par 5 mm (longueur en sens planaire) et 0,2 mm (épaisseur), préférentiellement de 10 à 50 par 5 mm (planaire) et 0,2 mm (épaisseur), et plus préférentiellement de 20 à 50 par 5 mm (planaire) et 0,2 mm (épaisseur). When the crimping is carried out by steam at high temperature, the nonwoven according to the invention has the characteristic that the crimping of the conjugate fibers oriented approximately parallel to the planar direction is developed in a substantially uniform manner in the direction of thickness. In a non-woven section taken in the direction of the thickness, among the areas delimited by a partition in three equal parts in the direction of the thickness, the number of fibers forming at least 1 spiral crimped turn is for example, in the central part (inner layer), from 5 to 50 by 5 mm (planar length) and 0.2 mm (thickness), preferably from 10 to 50 by 5 mm (planar) and 0.2 mm (thickness) and more preferably 20 to 50 per 5 mm (planar) and 0.2 mm (thickness).
Comme la majeure partie des fibres frisées ont leur axe orienté dans le sens planaire et que le nombre de frisures est uniforme dans le sens de l'épaisseur, le non-tissé manifeste une haute extensibilité (sans contenir de caoutchouc ou d'élastomère), et une bonne résistance opérationnelle (sans contenir d'adhésifs). Since most of the curled fibers have their axis oriented in the planar direction and the number of crimps is uniform in the direction of thickness, the nonwoven exhibits a high extensibility (without containing rubber or elastomer), and good operational resistance (without any adhesives).
Dans la présente description, par «domaines délimités par un partage en trois parts égales dans le sens de l'épaisseur», on entend les différents domaines obtenus quand on coupe le non-tissé en trois tranches égales orientées perpendiculairement à l'épaisseur. In the present description, by "areas delimited by a division into three equal parts in the direction of the thickness" is meant the different areas obtained when cutting the nonwoven into three equal slices oriented perpendicular to the thickness.
Dans le non-tissé, l'uniformité du frisage dans le sens de l'épaisseur peut être définie par le ratio d'incurvation de fibre. Par «ratio d'incurvation de fibre», on entend le rapport L2/L1 de la longueur de la fibre étirée bidimentionnellement L2 à la distance Ll des deux extrémités de la fibre à l'état frisé. Ce ratio d'incurvation de fibre (en particulier dans le domaine central dans le sens de l'épaisseur) est par exemple de l'ordre d'au moins 1,3 (par exemple de 1,35 à 5), préférentiellement de 1,4 à 4 (par exemple de 1,5 à 3,5), et plus préférentiellement de 1,6 à 3 (particulièrement de 1,8 à 2,5). In the nonwoven, the uniformity of the crimp in the direction of the thickness can be defined by the ratio of curvature of fiber. By "fiber curl ratio" is meant the ratio L2 / L1 of the length of the bilaterally stretched fiber L2 at the distance L1 of both ends of the fiber in the curled state. This fiber curvature ratio (in particular in the central region in the direction of the thickness) is for example of the order of at least 1.3 (for example from 1.35 to 5), preferably from 1 to , 4 to 4 (for example from 1.5 to 3.5), and more preferably from 1.6 to 3 (particularly from 1.8 to 2.5).
Lorsque le ratio d'incurvation de fibre est mesuré sur la base de micrographies électroniques de sections du non-tissé, la longueur de fibre L2 ne correspond pas à la longueur de la fibre qui serait obtenue si on étirait et rectilinéarisait la fibre frisée tridimensionnellement. Elle
correspond à la longueur de fibre sur cliché qui est obtenue quand on étire et rectilinéarise la fibre apparaissant frisée bidimensionnellement sur le cliché. Autrement dit, la longueur de fibre sur cliché qui est mesurée selon l'invention est inférieure à la longueur de fibre réelle. Lorsque le développement du frisage est à peu près uniforme dans le sens de l'épaisseur, le ratio d'incurvation de fibre est également uniforme dans le sens de l'épaisseur. L'uniformité du ratio d'incurvation de fibre peut être évaluée en comparant, dans une section prise dans le sens de l'épaisseur, les ratios d'incurvation de fibre obtenus dans les différentes couches délimitées par un partage en trois parts égales dans le sens de l'épaisseur. Ainsi, dans une section prise dans le sens de l'épaisseur, les ratios d'incurvation de fibre obtenus dans les différents domaines délimités par le partage en trois parts égales dans le sens de l'épaisseur se situent tous dans la plage précitée, et le rapport de la valeur minimale à la valeur maximale du ratio d'incurvation de fibre dans les différents domaines (rapport du domaine où le ratio d'incurvation de fibre est minimal au domaine où il est maximal) est par exemple de l'ordre d'au moins 75 % (par exemple de 75 à 100 %), préférentiellement de 80 à 99 %, et plus préférentiellement de 82 à 98 % (particulièrement de 85 à 97 %). When the fiber curl ratio is measured on the basis of electron micrographs of nonwoven sections, the length of fiber L2 does not correspond to the length of the fiber that would be obtained if the three-dimensional curled fiber was stretched and rectilinearized. She corresponds to the length of fiber on the plate that is obtained when stretching and rectilinearizes the fiber appearing curly bidimensionally on the plate. In other words, the fiber length on the plate that is measured according to the invention is less than the actual fiber length. When the development of the crimp is approximately uniform in the direction of the thickness, the fiber curvature ratio is also uniform in the direction of the thickness. The uniformity of the fiber curvature ratio can be evaluated by comparing, in a section taken in the direction of thickness, the fiber curl ratios obtained in the different layers delimited by a partition in three equal parts in the sense of thickness. Thus, in a section taken in the direction of the thickness, the fiber curvature ratios obtained in the various areas delimited by the division into three equal parts in the direction of the thickness are all within the aforementioned range, and the ratio of the minimum value to the maximum value of the fiber curvature ratio in the various domains (ratio of the area where the fiber curl ratio is minimal to the area where it is maximal) is for example of the order of at least 75% (for example 75 to 100%), preferably 80 to 99%, and more preferably 82 to 98% (particularly 85 to 97%).
Selon un mode de réalisation, le non tissé présente dans une section prise dans le sens de l'épaisseur, un ratio d'incurvation de fibre supérieur ou égal à 1,3 dans chacun des domaines délimités par un partage en trois parts égales dans le sens de l'épaisseur, et le rapport de la valeur minimale à la valeur maximale du ratio d'incurvation de fibre dans les différents domaines est supérieur à 75 %. According to one embodiment, the nonwoven has in a section taken in the direction of the thickness, a fiber curvature ratio of greater than or equal to 1.3 in each of the areas delimited by a division into three equal parts in the sense of thickness, and the ratio of the minimum value to the maximum value of the fiber curl ratio in the different fields is greater than 75%.
Comme méthode concrète de mesure du ratio d'incurvation de fibre et de son uniformité, on peut appliquer la méthode qui consiste à prendre une photo de la section du non- tissé au microscope électronique et à mesurer le ratio d'incurvation de fibre sur des domaines choisis au sein des différents domaines du partage en trois parts égales dans le sens de l'épaisseur. La mesure est réalisée, dans chacune des couches supérieures (domaine recto), interne (domaine central) et inférieure (domaine verso), sur des domaines qui, dans le sens de la longueur, font au moins 2 mm, et dans le sens de l'épaisseur, sont positionnés près du centre de chaque couche et ont la même épaisseur d'un domaine à l'autre. De plus, ces domaines de mesure sont parallèles dans le sens de l'épaisseur, et sont définis de telle sorte que chacun renferme au moins 100 fragments de fibres autorisant la mesure de leur ratio d'incurvation (de l'ordre préférentiellement d'au moins 300, et plus préférentiellement de 500 à 1000). Après avoir défini
ces domaines de mesure, on mesure le ratio d'incurvation de fibre de toutes les fibres situées dans le domaine et on calcule la valeur moyenne sur chaque domaine de mesure, puis on calcule l'uniformité du ratio d'incurvation de fibre en comparant le domaine montrant la valeur moyenne la plus grande et le domaine montrant la valeur moyenne la plus petite. As a concrete method of measuring the fiber curl ratio and its uniformity, the method of taking a photograph of the nonwoven section under the electron microscope and measuring the fiber curl ratio on selected areas within the different areas of sharing in three equal parts in the direction of thickness. The measurement is carried out in each of the upper layers (recto domain), internal (central domain) and lower (backside domain), on domains which, in the direction of the length, are at least 2 mm, and in the direction of thickness, are positioned near the center of each layer and have the same thickness from one area to another. In addition, these measurement domains are parallel in the direction of the thickness, and are defined such that each contains at least 100 fiber fragments allowing the measurement of their curvature ratio (of the order of preferably from minus 300, and more preferably from 500 to 1000). After setting these measurement domains, the fiber curvature ratio of all the fibers in the domain is measured and the average value is calculated on each measurement domain, then the uniformity of the fiber curl ratio is calculated by comparing the domain showing the largest mean value and the domain showing the smallest mean value.
La mesure du ratio d'incurvation de fibre et de son uniformité peut être effectuée selon la méthodologie suivante. On prend une photo (grossissement xlOO) d'une section de non- tissé au microscope électronique et, dans une partie où apparaissaient les fibres sur le cliché, on partage l'épaisseur en trois domaines égaux (couches recto, interne et verso), et près du centre de chaque domaine, on définit des domaines de mesure d'au moins 2 mm dans le sens de la longueur et contenant au moins 500 fragments de fibres mesurables. Sur ces domaines, on mesure d'une part la distance inter-extrémités (distance la plus courte) entre les deux extrémités de la fibre et d'autre part la longueur de fibre (longueur de la fibre sur cliché). The measurement of the fiber curl ratio and its uniformity can be performed according to the following methodology. Take a photo (magnification × 100) of a section of non-woven fabric under an electron microscope and, in a part where the fibers appeared on the plate, the thickness is divided into three equal areas (front, inner and back layers), and near the center of each domain, measuring domains of at least 2 mm in the length direction and containing at least 500 measurable fiber fragments are defined. On these domains, we measure on the one hand the inter-end distance (the shortest distance) between the two ends of the fiber and on the other hand the fiber length (length of the fiber on the plate).
Précisément, quand une extrémité de fibre émerge à la surface du non-tissé, elle est retenue telle quelle comme extrémité de mesure de la distance inter-extrémités; quand une extrémité de fibre plonge dans le non-tissé, on retient la partie limite de plongée dans le non-tissé (extrémité sur cliché) comme extrémité de mesure de la distance inter-extrémités. Specifically, when a fiber end emerges on the surface of the nonwoven, it is retained as such as the measuring end of the inter-end distance; when a fiber end is immersed in the nonwoven, the dive limit portion is held in the nonwoven (end plate) as the measuring end of the inter-end distance.
Parmi les fibres imagées, on exclut de la mesure celles sur lesquelles on ne peut isoler une continuité d'au moins 100 μιη. On calcule le ratio d'incurvation de fibre comme le rapport L2/L1 de la longueur de fibre L2 à la distance inter-extrémités Ll des fibres. Puis on calcule la moyenne sur chacune des couches recto, interne et verso du partage en trois parts égales dans le sens de l'épaisseur. On calcule enfin l'uniformité du ratio d'incurvation de fibre dans le sens de l'épaisseur à partir du rapport de ses valeurs maximale et minimale dans les différentes couches. Among the imaged fibers, we exclude from the measurement those on which we can not isolate a continuity of at least 100 μιη. The fiber curvature ratio is calculated as the L2 / L1 ratio of the fiber length L2 to the inter-end distance L1 of the fibers. Then we calculate the average on each of the front, inner and back layers of the partition in three equal parts in the direction of the thickness. Finally, the uniformity of the fiber curvature ratio in the direction of the thickness is calculated from the ratio of its maximum and minimum values in the different layers.
Le principe de la méthode de mesure de la longueur de fibre est illustré sur les figures 4-a et 4-b de la demande de brevet WO 2008/015972. The principle of the method of measurement of the fiber length is illustrated in FIGS. 4-a and 4-b of the patent application WO 2008/015972.
La Fig.4-(a) illustre le cas d'une fibre dont une extrémité émerge à la surface et l'autre extrémité plonge dans le non-tissé. La distance inter-extrémités Ll est ici la distance d'une extrémité de la fibre jusqu'à la partie limite de plongée dans le non-tissé. D'autre part, la longueur de fibre L2 est la longueur obtenue quand on étire bidimensionnellement, sur le cliché, la partie de la fibre observable (partie allant de l'extrémité de la fibre jusqu'à la partie de plongée dans le non-tissé).
La Fig.4-(b) illustre le cas d'une fibre dont les deux extrémités plongent dans le non- tissé. La distance inter-extrémités Ll est ici la distance des deux extrémités de la partie émergeant à la surface du non-tissé (extrémités sur cliché). D'autre part, la longueur de fibre L2 est la longueur obtenue quand on étire bidimensionnellement, sur le cliché, la fibre dans la partie émergeant à la surface du non-tissé. Fig.4- (a) illustrates the case of a fiber having one end emerging at the surface and the other end dipping into the nonwoven. The inter-end distance L1 is here the distance from one end of the fiber to the dive boundary portion in the nonwoven. On the other hand, the length of fiber L2 is the length obtained when the dimension of the observable fiber (part extending from the end of the fiber to the dive portion in the non-dimensional portion) is stretched bilaterally on the plate. woven). Fig.4- (b) illustrates the case of a fiber whose two ends plunge into the nonwoven. The inter-end distance L1 is here the distance of the two ends of the emerging portion to the surface of the nonwoven (ends on the plate). On the other hand, the length of fiber L2 is the length obtained when two-dimensionally stretched, on the plate, the fiber in the part emerging on the surface of the nonwoven.
Pour des fibres frisées en forme de serpentin, le pas moyen du serpentin est par exemple de l'ordre de 0,03 à 0,5 mm, préférentiellement de 0,03 à 0,3 mm, et plus préférentiellement de 0,05 à 0,2 mm. For curled fibers in the form of a coil, the average pitch of the coil is for example of the order of 0.03 to 0.5 mm, preferably of 0.03 to 0.3 mm, and more preferably of 0.05 to 0.2 mm.
Le non-tissé peut aussi contenir des fibres qui ne sont pas des fibres bicomposants. Parmi ces fibres additionnelles mono-composants, on peut par exemple citer les fibres de polymères déjà cités précédemment, mais aussi les fibres cellulosiques comme par exemple les fibres naturelles (laine de bois, laine de mouton, soie, chanvre), les fibres semi-synthétiques (notamment les fibres d'acétate telles que les fibres de triacétate) ou les fibres régénérées (rayonne, lyocell). Le titre moyen et la longueur moyenne des fibres mono-composants sont de préférence identiques à ceux des fibres bicomposants. On peut utiliser une seule espèce ou associer plusieurs espèces de ces fibres mono-composants. Parmi ces fibres mono-composants, la préférence va notamment aux fibres régénérées telles que les fibres de rayonne, aux fibres semi- synthétiques telles que les fibres d'acétate, aux fibres polyoléfîniques telles que les fibres de polypropylène ou de polyéthylène, aux fibres polyesters et aux fibres polyamides. The nonwoven may also contain fibers that are not bi-component fibers. Among these additional single-component fibers, mention may be made, for example, of the polymer fibers already mentioned above, but also the cellulosic fibers such as, for example, natural fibers (wood wool, sheep's wool, silk, hemp), semi-synthetic fibers. synthetic (especially acetate fibers such as triacetate fibers) or regenerated fibers (rayon, lyocell). The average titre and the average length of the single-component fibers are preferably identical to those of the two-component fibers. A single species can be used or several species of these single-component fibers can be combined. Among these single-component fibers, preference is given in particular to regenerated fibers such as rayon fibers, semi-synthetic fibers such as acetate fibers, polyolefin fibers such as polypropylene or polyethylene fibers, and polyester fibers. and polyamide fibers.
On préfère associer à des fibres bicomposants d'une famille chimique (par exemple de polyester) des fibres mono-composants de la même famille chimique. It is preferred to associate with two-component fibers of a chemical family (eg polyester) single-component fibers of the same chemical family.
Le rapport pondéral entre les fibres bicomposants et les fibres mono-composants est par exemple de l'ordre de 80/20 à 100/0 (par exemple de 80/20 à 99/1), préférentiellement de 90/10 à 100/0, et plus préférentiellement de 95/5 à 100/0. The weight ratio between the two-component fibers and the single-component fibers is, for example, of the order of 80/20 to 100/0 (for example from 80/20 to 99/1), preferably from 90/10 to 100/0. and more preferably 95/5 to 100/0.
Le non-tissé peut aussi contenir des actifs ou des additifs tels que des agents stabilisants, des filtres UV, des photostabilisants, des antioxydants, des antibactériens, des désodorisants, des parfums, des colorants, des charges, des agents antistatiques, des retardateurs de flamme, des plastifiants, des lubrifiants, ou des retardateurs de cristallisation. On peut utiliser un seul ou plusieurs de ces actifs ou additifs. Ces additifs peuvent aussi bien être supportés à la surface des fibres que contenus à l'intérieur des fibres. The nonwoven may also contain actives or additives such as stabilizers, UV filters, light stabilizers, antioxidants, antibacterials, deodorants, fragrances, dyes, fillers, antistatic agents, flame, plasticizers, lubricants, or crystallization retarders. One or more of these actives or additives can be used. These additives can be supported on the surface of the fibers as well as inside the fibers.
De manière générale, les actifs sont choisis parmi :
- les anti-bactériens tels que le Polymyxine B, les pénicillines (Amoxycilline), l'acide clavulanique, les tétracyclines, la Minocycline, la chlorotétracycline, les aminoglycosides, l'Amikacine, la Gentamicine, la Néomycine, l'argent et ses sels (Sulfadiazine argentique), les probiotiques ; In general, the assets are chosen from: anti-bacterials such as polymyxin B, penicillins (amoxycillin), clavulanic acid, tetracyclines, minocycline, chlorotetracycline, aminoglycosides, amikacin, gentamicin, neomycin, silver and its salts (Sulfadiazine argentic), probiotics;
- les antiseptiques tels que le mercurothiolate de sodium, l'éosine, la chlorhexidine, le borate de phénylmercure, l'eau oxygénée, la liqueur de Dakin, le triclosan, le biguanide, l'hexamidine, le thymol, le Lugol, la Povidone iodée, le Merbromine, le Chlorure de Benzalkonium et de Benzethonium, l'éthanol, l'isopropanol ; antiseptics such as sodium mercurothiolate, eosin, chlorhexidine, phenylmercury borate, hydrogen peroxide, Dakin liquor, triclosan, biguanide, hexamidine, thymol, Lugol, Povidone iodine, Merbromine, Benzalkonium and Benzethonium Chloride, ethanol, isopropanol;
- les anti-viraux tels que l'Acyclovir, le Famciclovir, le Ritonavir ; anti-virals such as Acyclovir, Famciclovir, Ritonavir;
- les anti fongiques tels que les polyènes, le Nystatin, l'Amphotéricine B, la anti fungal agents such as polyenes, Nystatin, Amphotericin B,
Natamycine, les imidazolés (Miconazole, Ketoconazole, Clotrimazole, Éconazole, Bifonazole, Butoconazole, Fenticonazole, Isoconazole, Oxiconazole, Sertaconazole, Sulconazole, Thiabendazole, Tioconazole), les triazolés (Fluconazole, Itraconazole, Ravuconazole, Posaconazole, Voriconazole), les allylamines, la Terbinafme, l'Amorolfine, la Naftifîne, la Buténafme ; Natamycin, imidazoles (Miconazole, Ketoconazole, Clotrimazole, Ecconazole, Bifonazole, Butoconazole, Fenticonazole, Isoconazole, Oxiconazole, Sertaconazole, Sulconazole, Thiabendazole, Tioconazole), triazoles (Fluconazole, Itraconazole, Ravuconazole, Posaconazole, Voriconazole), allylamines, Terbinafme, Amorolfine, Naftifine, Butenafme;
- la Flucytosine (antimétabolite), la Griséofulvine, la Caspofungine, la Micafungine ; Flucytosine (antimetabolite), Griseofulvin, Caspofungin, Micafungin;
- les anti-douleurs tels que le Paracétamol, la Codéine, le Dextropropoxyphène, le Tramadol, la Morphine et ses dérivés, les Corticoïdes et dérivés ; anti-pain agents such as paracetamol, codeine, dextropropoxyphene, tramadol, morphine and its derivatives, corticosteroids and derivatives;
- les anti-inflammatoires tels que les Glucocorticoïdes, les anti inflammatoires non stéroïdiens, l'Aspirine, l'Ibuprofène, le Kétoprofène, le Flurbiprofène, le Diclofénac, l'Acéclofénac, le Kétorolac, le Méloxicam, le Piroxicam, le Ténoxicam, le Naproxène, l'Indométacine, le Naproxcinod, le Nimésulide, le Célécoxib, l'Etoricoxib, le Parécoxib, le Rofécoxib, le Valdécoxib, la Phénylbutazone, l'acide niflumique, l'acide méfénamique, l'acide bêta-18-glycyrrhétinique ; anti-inflammatories such as glucocorticoids, nonsteroidal anti-inflammatory drugs, aspirin, ibuprofen, ketoprofen, flurbiprofen, diclofenac, aceclofenac, ketorolac, meloxicam, piroxicam, tenoxicam, Naproxen, Indomethacin, Naproxcinod, Nimesulide, Celecoxib, Etoricoxib, Parecoxib, Rofecoxib, Valdecoxib, Phenylbutazone, Niflumic acid, Mefenamic acid, Beta-18-glycyrrhetinic acid;
- les actifs favorisant la cicatrisation tels que le Rétinol, la Vitamine A, la Vitamine - the assets promoting healing such as Retinol, Vitamin A, Vitamin
E, la N-acétyl-hydroxyproline, les extraits de Centella Asiatica, la papaïne, les silicones, les huiles essentielles de thym, de niaouli, de romarin et de sauge, l'acide hyaluronique, les oligosaccharides polysulfatés synthétiques ayant 1 à 4 unités oses tels que le sel de potassium du sucrose octasulfaté, le sel d'argent du sucrose octasulfaté ou le sucralfate, l'AUantoïne, la metformine ; E, N-acetyl-hydroxyproline, extracts of Centella Asiatica, papain, silicones, essential oils of thyme, niaouli, rosemary and sage, hyaluronic acid, synthetic polysulfated oligosaccharides having 1 to 4 units such as the potassium salt of octasulfated sucrose, the silver salt of octasulfated sucrose or sucralfate, antantoin, metformin;
- les actifs restructurants (par exemple resctructurants des phanères) tels que les dérivés de silice, la vitamine E, la camomille, le calcium, l'extrait de prêle, le Lipester de soie ;
- les anesthésiques tels que la benzocaïne, la lidocaïne, la dibucaïne, le chlorhydrate de pramoxine, la bupivacaïne, la mepivacaïne, la prilocaïne, l'étidocaïne. - restructuring assets (for example rescutants of dander) such as silica derivatives, vitamin E, chamomile, calcium, horsetail extract, silk Lipester; anesthetics such as benzocaine, lidocaine, dibucaine, pramoxine hydrochloride, bupivacaine, mepivacaine, prilocaine and etidocaine.
-les hémostatiques tels que le fïbrinogène, le facteur XIII, la fïbronectine, la thrombine, l'aprotinine bovine, l'acide tranexamique, le collagène, les aldéhydes, les cyanoacrylates, le polyéthylène glycol, les alginates, la cellulose, les polysaccharides. haemostatics such as fibrinogen, factor XIII, fibronectin, thrombin, bovine aprotinin, tranexamic acid, collagen, aldehydes, cyanoacrylates, polyethylene glycol, alginates, cellulose, polysaccharides.
Les autres propriétés mécaniques du non tissé seront de préférence les suivantes. The other mechanical properties of the nonwoven will preferably be as follows.
L'épaisseur du non tissé sera avantageusement comprise entre 0,25 et 5 mm, de préférence entre 0,4 et 2,5 mm et tout particulièrement entre 0,5 et 1,5 mm. L'épaisseur peut être mesurée selon la norme EN 9073-2. The thickness of the nonwoven fabric is advantageously between 0.25 and 5 mm, preferably between 0.4 and 2.5 mm and very particularly between 0.5 and 1.5 mm. The thickness can be measured according to EN 9073-2.
L' autoadhérence de la bande selon l'invention est obtenue grâce à la présence de nombreuses fibres à l'état partiellement libre à la surface des non tissés, les fibres de surface s 'enchevêtrant mutuellement au moment de la superposition de la bande sur elle-même. Pour obtenir cette propriété d'autoadhérence sans altérer les propriétés de déchirabilité et d'extensibilité, le nombre de fibres frisées, notamment en forme de serpentin ou de boucle, à la surface du non tissé, est avantageusement supérieur à 10 fibres frisées/cm2, et de préférence compris entre 10 et 50 fibres frisées/cm2. Pour la réalisation du pansement selon l'invention, on préférera un nombre de fibres frisées à la surface du non tissé compris entre 10 à 35 fibres frisées/cm2. The self-adhesion of the web according to the invention is achieved by the presence of many fibers in the partially free state on the surface of the nonwovens, the surface fibers becoming entangled with each other at the time of the superimposition of the web on it. -even. To obtain this self-adhesion property without altering the properties of tearability and extensibility, the number of crimped fibers, in particular in the form of a coil or a loop, on the surface of the nonwoven is advantageously greater than 10 crimped fibers / cm 2. and preferably between 10 and 50 crimped fibers / cm 2 . For the production of the dressing according to the invention, a number of crimped fibers on the nonwoven surface of between 10 and 35 crimped fibers / cm 2 will be preferred.
Le nombre de fibres frisées à la surface du non tissé peut être déterminé comme suit. The number of crimped fibers on the surface of the nonwoven can be determined as follows.
On prend une photo (grossissement xlOO) de la surface du non-tissé au microscope électronique, et on compte le nombre de fibres frisées (fibres faisant au moins un tour de spirale en boucle ou de serpentins formés à la surface du non-tissé), sur une aire unitaire de 1 cm2 de surface de fibres imagées. La mesure peut être effectuée en cinq endroits arbitraires, et on calcule le nombre moyen de fibres bouclées arrondie à l'unité la plus proche. Take a picture (magnification × 100) of the surface of the nonwoven with the electron microscope, and count the number of crimped fibers (fibers making at least one round of spiral loop or coils formed on the surface of the nonwoven) , on a unit area of 1 cm 2 of surface of imaged fibers. The measurement can be made in five arbitrary places, and the average number of looped fibers rounded to the nearest unit is calculated.
La caractérisation de Γ autoadhérence de la bande est évaluée visuellement. Une bande de non tissé présentant une largeur de 15 mm est enroulée en l'étirant légèrement sur le bout du doigt de façon à former trois spires puis déchirée manuellement. Le pouvoir auto- agrippant est alors estimée. Il résulte de ce test que les bandes restent sur le doigt au moins 30 minutes. The self-adhesion characterization of the band is evaluated visually. A strip of nonwoven having a width of 15 mm is wound by stretching it slightly on the fingertip so as to form three turns and then torn manually. The self-gripping power is then estimated. It follows from this test that the bands remain on the finger for at least 30 minutes.
Selon une variante de la présente invention, on pourra ajouter au non tissé une (ou plusieurs) couche(s) supplémentaire(s) choisie(s) parmi les matériaux textiles, les matériaux
alvéolaires, les films les matériaux absorbants ou leurs combinaisons. Cette couche supplémentaire permet d'améliorer si nécessaire, les propriétés de la bande autoadhérente élastique, par exemple en adaptant ses capacités d'absorption, d'amortissement, de conformabilité, de rigidité, ou d'occlusivité. According to a variant of the present invention, it will be possible to add to the nonwoven one (or more) additional layer (s) chosen (s) from the textile materials, the materials alveolar, films, absorbent materials or their combinations. This additional layer makes it possible to improve, if necessary, the properties of the self-adhesive elastic band, for example by adapting its absorption, damping, conformability, rigidity or occlusivity capacities.
Parmi les matériaux, on pourra utiliser des matériaux à base de fibres synthétiques ou naturelles. On peut citer les tissés, les non tissés, les tricots, les tricots 3D, les films, les mousses et leurs combinaisons. Among the materials, it will be possible to use materials based on synthetic or natural fibers. We can mention woven fabrics, nonwovens, knits, 3D knits, films, foams and their combinations.
La couche supplémentaire pourra contenir éventuellement des agents actifs qui contribuent à l'amélioration de la cicatrisation de la plaie ou qui permettent de diminuer la douleur, ou encore des agents antibactériens. Selon une variante de réalisation, on pourra introduire dans la couche supplémentaire des fibres antibactériennes, par exemple des fibres argent, ou imprégner celle-ci avec un antibactérien par exemple du triclosan. The additional layer may optionally contain active agents that contribute to improving the healing of the wound or that can reduce the pain, or antibacterial agents. According to an alternative embodiment, it is possible to introduce into the additional layer antibacterial fibers, for example silver fibers, or to impregnate the latter with an antibacterial agent, for example triclosan.
La structure aérée et la présence de boucles confèrent à la bande de l'invention d'excellentes propriétés d'amortissement et de conformabilité. The aerated structure and the presence of loops confer on the strip of the invention excellent damping and conformability properties.
Exemple : Pansement selon l'invention Example: Dressing according to the invention
L'exemple utilise un non tissé, à base de fibres bicomposants asymétriques frisées, fabriqués selon l'enseignement de la demande de brevet WO 2008/015972. Ce non tissé peut être de référence SR 0046 de la société Kuraray. Ce non tissé est réalisé à partir de la fibre, de type côte à côte, à base de copolymères polyesters de la société Kuraray dont la référence est PN - 780. The example uses a nonwoven, based on two-component asymmetric crimped fibers, manufactured according to the teaching of the patent application WO 2008/015972. This nonwoven can be reference SR 0046 from Kuraray. This nonwoven is made from the side-by-side fiber, based on polyester copolymers of the company Kuraray whose reference is PN-780.
Ce non tissé présente les propriétés et les caractéristiques suivantes : This nonwoven has the following properties and characteristics:
Non tissé Nonwoven
Grammage (norme EN 9073-1) 90 g/m2 Weight (EN 9073-1 standard) 90 g / m 2
Epaisseur (norme EN 9073-2) 1,15 mm Thickness (EN 9073-2 standard) 1.15 mm
Elongation longitudinale (norme EN 9073-3)98 % Longitudinal elongation (EN 9073-3 standard) 98%
- Nombre de fibres frisées - Number of curly fibers
à la surface du non tissé* 19 /cm2 on the surface of non woven fabric * 19 / cm 2
* mesuré selon la méthode décrite précédemment
3. Performance des pansements * measured according to the method previously described 3. Performance of dressings
La performance de pansements constitués d'une bande de non tissé selon l'invention sur la coagulation du sang a été évaluée. Du sang complet de mouton a été mis en contact avec une bande de non tissé selon l'invention à un ratio de lcm2/mL dans des tubes à essais incubés à 37 ±1°C. Un tube à essai témoin sans bande est testé dans les mêmes conditions comme contrôle négatif. Après l'incorporation du sang, les tubes à essai sont retournés doucement toutes les minutes jusqu'à ce qu'un caillot sanguin soit observé. Le temps de coagulation est enregistré pour l'article testé (4 essais). Le temps de coagulation moyen du sang de mouton en présence du non tissé selon l'invention était de 13 minutes trente secondes. Le temps de coagulation moyen du sang de mouton dans le tube à essai témoin était d'environ 26 minutes trente secondes.
The performance of dressings consisting of a web of nonwoven according to the invention on the coagulation of blood was evaluated. Whole sheep blood was contacted with a nonwoven web according to the invention at a ratio of 1 cm 2 / mL in test tubes incubated at 37 ± 1 ° C. A control tube without tape is tested under the same conditions as a negative control. After blood incorporation, the test tubes are gently inverted every minute until a blood clot is observed. The coagulation time is recorded for the article tested (4 trials). The average coagulation time of the sheep blood in the presence of the nonwoven according to the invention was 13 minutes thirty seconds. The mean clotting time of the sheep blood in the control test tube was about 26 minutes thirty seconds.
Claims
1. Pansement comprenant au moins une bande constitué d'un non tissé de fibres frisées obtenues à partir de fibres courtes conjuguées, dans laquelle 1. Dressing comprising at least one strip consisting of a nonwoven of crimped fibers obtained from conjugated short fibers, in which
- le non tissé a un grammage compris entre 10 g/m2 et 300 g/m2, the nonwoven has a basis weight of between 10 g / m 2 and 300 g / m 2 ,
- lesdites fibres sont frisées de façon uniforme dans le sens de l'épaisseur des non tissés, et présentent un rayon de courbure moyen compris entre 10 et 200 micromètres, et said fibers are uniformly crimped in the direction of the thickness of the nonwovens, and have an average radius of curvature of between 10 and 200 microns, and
- le nombre de fibres frisées à la surface de chacun des non-tissés est supérieur à 10 fibres frisées/cm the number of crimped fibers on the surface of each of the nonwovens is greater than 10 curled fibers / cm
pour son utilisation pour favoriser et/ou activer l'hémostase for use in promoting and / or activating hemostasis
2. Pansement selon la revendication 1, caractérisée en ce que les fibres courtes conjuguées sont bicomposants, les deux composants les constituant étant des polymères qui présentent un point de ramollissement supérieur ou égal à 100°C, lesdits polymères étant choisis parmi les polymères polypropyléniques, les polymères polyesters et/ou les polymères polyamides, et de préférence sont deux polymères polyesters aromatiques différents. 2. Dressing according to claim 1, characterized in that the conjugated short fibers are bicomponent, the two components constituting them being polymers which have a softening point greater than or equal to 100 ° C, said polymers being chosen from polypropylenic polymers, the polyester polymers and / or the polyamide polymers, and preferably are two different aromatic polyester polymers.
3. Pansement selon la revendication 2, caractérisée en ce que les fibres bicomposants ont une structure de type côte à côte et sont constituées d'un premier polymère qui est un polyéthylène téréphtalate, et d'un second polymère qui est un copolymère d'un alkylène arylate avec l'acide isophtalique et/ou du diéthylène glycol. 3. Dressing according to claim 2, characterized in that the bicomponent fibers have a side-by-side type structure and consist of a first polymer which is a polyethylene terephthalate, and a second polymer which is a copolymer of a alkylene arylate with isophthalic acid and / or diethylene glycol.
4. Pansement selon la revendication 1, caractérisée en ce que le titre moyen des fibres courtes conjuguées est compris entre 1 et 5 dtex, de préférence entre 1,5 et 3 dtex, et la longueur moyenne des fibres courtes conjuguées est comprise entre 10 à 100 mm, et de préférence entre 40 et 60 mm. 4. Dressing according to claim 1, characterized in that the average titer of the conjugated short fibers is between 1 and 5 dtex, preferably between 1.5 and 3 dtex, and the average length of the conjugated short fibers is between 10 to 100 mm, and preferably between 40 and 60 mm.
5. Pansement selon la revendication 1, caractérisée en ce que les fibres frisées présentent un rayon de courbure moyen compris entre 50 et 160 microns, et de préférence entre 70 et 130 microns.
2 5. Dressing according to claim 1, characterized in that the crimped fibers have an average radius of curvature of between 50 and 160 microns, and preferably between 70 and 130 microns. 2
6. Pansement selon la revendication 1, caractérisée en ce que le non tissé a un grammage compris entre 50 et 150 g/m2 et de préférence entre 70 et 110 g/m2. 6. Dressing according to claim 1, characterized in that the nonwoven has a basis weight between 50 and 150 g / m 2 and preferably between 70 and 110 g / m 2 .
7. Pansement selon la revendication 1, caractérisée en ce que le nombre de fibres frisées à la surface de chacun des non tissés est compris entre 10 et 50 fibres frisées / cm2 et de préférence entre 10 et 35 fibres frisées / cm2. 7. Dressing according to claim 1, characterized in that the number of crimped fibers on the surface of each of the nonwovens is between 10 and 50 crimped fibers / cm 2 and preferably between 10 and 35 crimped fibers / cm 2 .
8. Pansement selon la revendication 1, caractérisée en ce que le non tissé présente dans une section prise dans le sens de l'épaisseur, un ratio d'incurvation de fibre supérieur ou égal à 1,3 dans chacun des domaines délimités par un partage en trois parts égales dans le sens de l'épaisseur, et le rapport de la valeur minimale à la valeur maximale du ratio d'incurvation de fibre dans les différents domaines est supérieur à 75 %. 8. Dressing according to claim 1, characterized in that the nonwoven has in a section taken in the direction of the thickness, a fiber curvature ratio greater than or equal to 1.3 in each of the areas delimited by a partition in three equal parts in the thickness direction, and the ratio of the minimum value to the maximum value of the fiber curl ratio in the various fields is greater than 75%.
9. Pansement selon la revendication 1, caractérisée en ce qu'elle comprend une couche supplémentaire choisie parmi les matériaux textiles, les matériaux alvéolaires, les films ou leurs combinaisons. 9. Dressing according to claim 1, characterized in that it comprises an additional layer selected from textile materials, cellular materials, films or combinations thereof.
10. Pansement selon la revendication 1, caractérisée en ce que la bande contient des additifs ou des actifs.
10. Dressing according to claim 1, characterized in that the band contains additives or active ingredients.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/FR2016/050529 WO2017153640A1 (en) | 2016-03-08 | 2016-03-08 | Dressing in the form of a self-adhesive tape |
EP16714484.9A EP3426207A1 (en) | 2016-03-08 | 2016-03-08 | Dressing in the form of a self-adhesive tape |
FR1770216A FR3048607A1 (en) | 2016-03-08 | 2017-03-06 | DRESSING IN THE FORM OF A SELF-ADHESIVE BAND |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/FR2016/050529 WO2017153640A1 (en) | 2016-03-08 | 2016-03-08 | Dressing in the form of a self-adhesive tape |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017153640A1 true WO2017153640A1 (en) | 2017-09-14 |
Family
ID=55661475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2016/050529 WO2017153640A1 (en) | 2016-03-08 | 2016-03-08 | Dressing in the form of a self-adhesive tape |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3426207A1 (en) |
FR (1) | FR3048607A1 (en) |
WO (1) | WO2017153640A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004046442A1 (en) * | 2002-11-21 | 2004-06-03 | Invista Technologies S.À.R.L. | High stretch recovery non-woven fabric and process for preparing |
WO2008015972A1 (en) | 2006-08-04 | 2008-02-07 | Kuraray Kuraflex Co., Ltd. | Stretch nonwoven fabric and tapes |
US20110280919A1 (en) * | 2010-05-17 | 2011-11-17 | Olajompo Moloye-Olabisi | Reinforced Absorbable Synthethic Matrix for Hemostatic Applications |
US20110282364A1 (en) * | 2010-05-17 | 2011-11-17 | Olajompo Moloye-Olabisi | Reinforced Absorbable Multi-Layered Fabric for Hemostatic Applications |
WO2014033418A1 (en) * | 2012-09-03 | 2014-03-06 | Laboratoires Urgo | Novel elastic bandage having improved support properties |
-
2016
- 2016-03-08 WO PCT/FR2016/050529 patent/WO2017153640A1/en active Application Filing
- 2016-03-08 EP EP16714484.9A patent/EP3426207A1/en not_active Withdrawn
-
2017
- 2017-03-06 FR FR1770216A patent/FR3048607A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004046442A1 (en) * | 2002-11-21 | 2004-06-03 | Invista Technologies S.À.R.L. | High stretch recovery non-woven fabric and process for preparing |
WO2008015972A1 (en) | 2006-08-04 | 2008-02-07 | Kuraray Kuraflex Co., Ltd. | Stretch nonwoven fabric and tapes |
EP2058424A1 (en) * | 2006-08-04 | 2009-05-13 | Kuraray Kuraflex Co., Ltd. | Stretch nonwoven fabric and tapes |
US20110280919A1 (en) * | 2010-05-17 | 2011-11-17 | Olajompo Moloye-Olabisi | Reinforced Absorbable Synthethic Matrix for Hemostatic Applications |
US20110282364A1 (en) * | 2010-05-17 | 2011-11-17 | Olajompo Moloye-Olabisi | Reinforced Absorbable Multi-Layered Fabric for Hemostatic Applications |
WO2014033418A1 (en) * | 2012-09-03 | 2014-03-06 | Laboratoires Urgo | Novel elastic bandage having improved support properties |
Also Published As
Publication number | Publication date |
---|---|
EP3426207A1 (en) | 2019-01-16 |
FR3048607A1 (en) | 2017-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2832885C (en) | Very absorbent, thin adhesive dressing, and uses thereof for the treatment of chronic wounds | |
JP2010520377A (en) | Nonwoven fiber fabric | |
CA2878869C (en) | Dressing having the controlled release of active agents | |
CH625702A5 (en) | ||
EP2892483B1 (en) | Novel elastic bandage having improved support properties | |
EP2892482B1 (en) | Novel self-adhesive elastic bandage that can be used, in particular, for the treatment and prevention of diseases of the veins | |
WO2013153225A1 (en) | Powder forming a dressing and corresponding absorbing material | |
EP3426207A1 (en) | Dressing in the form of a self-adhesive tape | |
EP2892484B1 (en) | Novel elastic bandage that can be used, in particular, for the treatment and prevention of diseases of the veins | |
FR2959418A1 (en) | BANDOVER COMPRISING AN ADHESIVE HYDROCOLLOID MASS | |
EP3082887B1 (en) | Composite material for filling cavity wounds | |
FR3030225A1 (en) | DRESSING COMPRISING A SUPPORT AND A HYDROPHOBIC ELASTOMERIC MATRIX | |
WO2015092314A1 (en) | Composite material for filling cavity wounds | |
EP3515386B1 (en) | Absorbent dressing comprising a water-disintegratable superabsorbent nonwoven | |
FR3048617B1 (en) | DRESSING SUITABLE FOR SENSITIVE SKIN | |
FR3068882B1 (en) | INTERFACE DRESSING | |
WO2017017386A1 (en) | Bandage comprising a support and a hydrophobic elastomeric matrix. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016714484 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016714484 Country of ref document: EP Effective date: 20181008 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16714484 Country of ref document: EP Kind code of ref document: A1 |